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1.1 GENERAL INTRODUCTION. 
Supported by the firmly established connection between elevated serum 
cholesterol levels and increased risk of coronary heart disease. both physicians 
and patients are striving for better cholesterol control (1). A better 
understanding of the mechanisms of cholesterol metabolism will provide 
insight in the means of lowering cholesterol levels. The regulation of 
cholesterol metabolism is multifactorial, with diet and hormones playing 
important roles. The influence of hormones on lipid metabolism is of major 
clinical interest, because abnormalities of various hormone secretions may 
induce lipoprotein aberrations which possibly account for the atherogenic risk 
accompanying common medical disorders such as obesity, diabetes mellitus 
and hypothyroidism. Despite a large number of data from clinical, 
epidemiological, animal and autopsy studies linking hypothyroidism to the 
development of atherosclerotic disease, the precise relationship between the 
two and the pathogenetic mechanisms involved are poorly understood (2). 
This thesis will focus on the influence of the hormonal changes that occur 
during hypothyroidism on lipoprotein metabolism. Before describing what is 
known about the lipid metabolism in hypothyroidism, the metabolism of 
relevant lipoproteins in the normal, euthyroid state will be reviewed briefly. 
1.2 PLASMA LIPOPROTEIN METABOLISM. 
Most pathways of plasma lipid transport originate in or converge upon the 
liver, making that organ central to the lipoprotein metabolism (3; Figure 1.1). 
In the fasted state, very low-density lipoprotein (VLDL) is the main plasma 
carrier of triglycerides (TG). It is continuously produced and secreted by the 
liver. After synthesis and excretion, the particle is metabolized by lipoprotein 
lipase (LPL), an enzyme predominantly present at the surface of endothelial 
cells, in muscle and adipose tissue. LPL catalyzes the extrahepatic elimination 
of TG from the plasma (4); it breaks down the TG content of VLDL and 
produces intermediate-density lipoprotein (IDL)(5). During this process, the 
VLDL surface components, phospholipids and apoproteins, are transferred to 
high-density lipoprotein (HDL). IDL can be removed from the plasma by two 
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pathways, it may either be removed by the liver, especially larger VLDL 
particles are taken up directly after delipidation (6), or further converted to 
low-density lipoprotein (LDL), Hepatic Lipase (HL) is thought to mediate this 
latter process (7,8). The synthesis of large TG enriched VLDL is promoted by 
high carbohydrate intake and alcohol (9). Cholesterol feeding produces a 
situation with cholesterol-ester enriched small VLDL-particles which are 
preferably converted through IDL to LDL (10). LDL is the major cholesterol 
transporting lipoprotein in plasma. Elevated plasma LDL-cholesterol levels 
are associated with the development of premature atherosclerosis. A central 
role in the hepatic clearance of lipoproteins from the blood stream is played 
by the LDL-receptor (ll). It is not only responsible for the uptake of LDL, 
but may contribute to the clearance of other lipoproteins that contain 
apolipoprotein (apo) B-100, like IDL The activity of LDL-receptors in 
hepatocytes is, among others, regulated by the cellular content of cholesterol 
(12). 
HDL's form a heterogeneous population of particles, derived from many 
sources. Part of the plasma HDL originates from surface remnants released 
during lipolysis of VLDL and chylomicrons. An inverse relationship between 
the plasma concentration of HDL and TG is well established (13,14). Another 
amount of HDL is produced as nascent-particles of intestinal or liver origin. 
Once the nascent HDL-particles reach the circulation, they accumulate 
cholesterol from peripheral tissues. In humans a major function of most 
lipoproteins is to deliver lipids to cells, but the main metabolic role of HDL is 
the acceptance of excess cholesterol from peripheral cells (15). A high 
concentration of plasma HDL-cholesterol is thought to be favorable, and 
related to regression of atherosclerosis. The major protein in HDL is apo A-I: 
it performs many roles, like being a cofactor for the plasma cholesterol 
esterifying enzyme lecithin:cholesterol acyl transferase (LCAT). LCAT 
activity is involved in the acceptance of cholesterol by HDL, for instance from 
peripheral tissue (9). Once HDL3 is converted to HDLz-like particles by 
lipolysis of VLDL, LCAT stimulates the formation of mature HDLz. 
Cholesteryl-esters can be transferred and exchanged between lipoproteins; this 
process is catalyzed by cholesteryl-ester transfer protein (CETP) (16). CETP 
facilitates the transfer of the ester from HDL into less dense VLDL and LDL 
in exchange for triglycerides, to convert HDLz to HDL3-Iike particles. The 
delivery of cholesterol from HDLz to the liver has been suggested to be 
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modulated by HL. The mechanism by which HL is involved in HDL 
metabolism is not exactly known. Like LPL, the enzyme hydrolyses TG and 
phospholipids, but appears to be more effective towards phospholipids. It has 
been proposed that HL modulates the flux of unesterified cholesterol between 
HDL and tissue by affecting the phospholipid-free cholesterol ratio in the 
particle (8). A strong negative correlation exists between HL-activity and HDL-
levels. Absence of HL-activity is associated with HDL levels, especially HDL2. 
LIVER 
Figure 1.1: Metabolism of VLDL and LDL and the role of hepatic lipase (HL) and 
lipoprotein lipase (LPL) under normal conditions. 
1.3.1LIPID METABOLISM AND THYROID FUNCTION. 
It has been recognized for almost 70 years that hypothyroidism influences 
cholesterol metabolism (17 -19). Plasma lipoproteins represent one of the most 
sensitive target systems for thyroid hormones: alterations in lipoprotein 
metabolism are an indicator of thyroid function. Hypercholesterolemia is 
typically found in individuals with hypothyroidism. Conversely hypochol-
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esterolemia is associated with hyperthyroidism. The hypercholesterolemia of 
hypothyroidism can be an important risk factor for atherosclerosis. 
L3.2PLASMA LIPOPROTEIN CONCENTRATIONS IN 
HYPO THYROIDS. 
The dyslipoproteinemia of hypothyroid patients is characterized by an 
increased plasma concentration of total cholesterol, because of an increase in 
the concentration of plasma LDL-cholesterol (20-22; Figure 1.2). The major 
apolipoprotein in LDL, apo B-100, is also markedly increased (22,23). Less 
uniform are the effects of hypothyroidism on plasma HDL concentration. In 
man HDL levels have been reported to be either increased (24), normal (20) 
or even decreased (25). Apo A-I, the main apolipoprotein in HDL, is reported 
to be increased in the hypothyroid state, while the effects on apo A-Il, an 
other protein of HDL are less clear (22,23). In hypothyroid rats, both LDL 
and HDL are increased (26); in these animals apo A-I mRNA levels in the 
liver can be enhanced by thyroxin, while liver apo A-U mRNA will decrease 
(28). Plasma TG levels are normal or only moderately elevated in most 
hypothyroid patients (27). In human plasma apo E is mainly associated with 
VLDL and HDL. Apo E is reported not to change in the hypothyroid patients 
(28) (neither is liver apo E mRNA influenced by alteration in thyroid status in 
the rat, 29). The hyperlipoproteinemia of hypothyroidism is reversible by 
restoration of the euthyroid state (30). 
L3.3LIPOPROTEIN METABOLISM IN HYPOTHYROIDISM. 
The actions of thyroid hormone, or a deficiency of this hormone, on the liver 
are likely to be of central importance to its effects on lipoprotein metabolism. 
In patients with primary hypothyroidism the hypercholesterolemia is mainly 
caused by a decreased catabolism of LDL (20); a diminished removal of 13II-
Iabeled LDL was shown to exist in these patients (31,32; Figure 1.2). Studies 
in humans as well as in vitro experiments indicate that the reduced fractional 
catabolic rate of LDL results from a modulation of the expression of the LDL-
receptor in the liver (33-35). This organ possesses over seventy percent of the 
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Normal Hypothyroidism 
Figure 1.2: Lipoprotein metabolism affected by hypothyroidism. During hypothyroidism 
both the activity of hepatic lipase (HL) and the activity of the LDL-receptor are 
decreased (indicated by X). This results in an increase in both IDL and LDL. 
The effect of hypothyroidism on lipoprotein lipase (LPL) activity is uncertain. 
body's LDL-receptor. In rats, replacement therapy with thyroxin increases 
LDL-receptor activity, in parallel with an increase in LDL-receptor mRNA 
(36). 
The majority of body cholesterol synthesis occurs in the liver. It is decreased 
in hypothyroid patients (20). In hypothyroid rats a decreased activity of HMG-
CoA reductase was found (37). As HMG-CoA reductase catalyses the rate 
limiting reaction in cholesterol synthesis, the decreased activity of this 
enzyme might be responsible for the low cholesterol production rate in 
hypothyroidism. Nonetheless, obese hypothyroid subjects show elevated 
synthesis rates of cholesterol (20), which is probably due to a habitual 
excessive intake of calories. 
The effects of thyroid hormone deficiency on the concentration of plasma 
LDL-cholesterol are well recognized. In contrast, there are conflicting reports 
about the influence of the hypothyroid state on the metabolism of plasma 
triglycerides. Non-obese hypothyroid patients generally have normal levels of 
TG, while obese patients often have hypertriglyceridemia (38). In these 
patients synthesis of VLDL by the liver appears to be increased (38). The 
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proposed mechanism is a lessened peripheral utilization of FF A and glucose, 
shunting them to TG synthesis. A relationship between TG concentration and 
severity of hypothyroidism has been suggested (39), but is not always 
confirmed ( 40). Perfused livers from hypothyroid rats, exhibit an increased 
rate of TG secretion. when compared to euthyroid rats (41). Another 
mechanism whereby hypothyroidism might increase plasma TG, is a decreased 
LPL-activity. However, the results from studies on LPL-activity during 
hypothyroidism are as conflicting as TG concentrations: some find a decreased 
activity (27,41), others do not see any influence of either thyroid hormone 
deficiency or substitution (38,42). 
In contrast to these conflicting results on LPL, the activity of HL is generally 
reported to be decreased in patients as well as in rats with hypothyroidism ( 41-
44: Figure 1.2). As HL catalyzes the interconversion of HDL-subclasses, 
hypothyroidism influences the catabolism of HDL2- to HDL3-particles 
(41,43,45). In hypothyroids, with a decreased HL-activity. HDL3 is little 
affected in amount and cholesterol content, while HDL2 fluctuates inversely 
with thyroid hormone concentration (44,46,47). Another result of the 
decreased HL-activity in hypothyroids is an increase in the plasma 
concentration of IDL ( 48,49) and small VLDL indicating a defective 
conversion of VLDL to LDL (50). 
Next to these effects of hypothyroidism on cholesterol homeostasis in the 
liver. some extra hepatic effects of hypothyroidism are reported. e.g. a 
relatively high absorption of cholesterol in the intestine of patients with 
hypothyroidism, which will add to the hypercholesterolemia of 
hypothyroidism (20). However in hypothyroid rats the percentage of 
cholesterol that was absorbed in the intestine was not changed (51). The 
activities of LCA T (52,53) and CETP (23) have also been reported to be 
moderately decreased in severe hypothyroidism. 
1.4 GROWTH HORMONE ACTIVITY DURING 
HYPOTHYROIDISM. 
GH secretion is dependent on thyroid hormone availability. In hypothyroid 
patients and in hypothyroid rats. the secretion of GH is decreased, both 
spontaneously (54,55), and in response to stimuli (56-58). In rats it was shown 
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that the decreased GH secretion is associated with a marked reduction in 
hypothalamic content of GH-releasing hormone (55) and a reduced synthesis 
of GH in the pituitary gland (59-61). This decrease in GH synthesis results in a 
diminished GH content of the hypophysis (62). Experiments with pituitary 
tumor cells show that thyroid hormone stimulates GH synthesis at the level of 
GH gene transcription (63.64). This effect of thyroid hormone is mediated via 
the thyroid hormone receptor, in combination with cell specific response 
elements which stimulate GH gene expression (65). Both production and 
secretion of GH are restored to normal by thyroid hormone replacement in 
vivo (66-68). 
Many effects of GH, like stimulation of growth, are mediated by Insulin-like 
Growth Factor I (IGF-I), previously called somatomedin-c (69). The IGF-I 
concentration in plasma shows a strong (but not an absolute) dependence on 
GH; e.g it also responds to thyroid hormone and nutritional status (70). In 
hypothyroid men plasma IGF-I concentrations are diminished (71 ), as the 
result of a decreased GH secretion (54). Evidently thyroid hormones are 
required for secretion and activity of GH. This means that in hypothyroid 
subjects both thyroid hormone and GH are decreased and both hormones will 
show their effects when the euthyroid state is restored. 
1.5 EFFECTS OF THYROID HORMONE SUBSTITUTION ON 
LIPID METABOLISM IN HYPOPHYSECTOMIZED RATS. 
Thyroid hormone substitution treatment in primary hypothyroidism restores 
at least thyroid hormone- and GH-activity. Observation of the effects of 
thyroid hormone substitution in hypophysectomized rats will help to 
understand the effects of thyroid hormone in cholesterol metabolism, without 
the intermingling with GH effects. 
Early in the seventies, it was reported that in hypophysectomized rats, daily 
treatment with 2 mg of thyroid extract could not prevent hypercholester-
olemia, but did lessen it by comparison with that observed in the untreated 
hypophysectomized rats (72). This suggests that more than thyroid hormone is 
necessary to normalize cholesterol metabolism of hypophysectomized rats. T 3 
replacement studies were done in these rats, to study the effect of thyroid 
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hormone on detailed parts of cholesterol metabolism (73,74). The increase of 
LDL-cholesterol by hypophysectomy was significantly rectified but the 
normal level could not be maintained, whilst the decreased HDL level was not 
at all affected by thyroid hormones (73). Administration of T3 to the hypo-
physectomized rats resulted in an increase in hepatic LDL-receptor mRNA 
levels (74); this increase was observed within 24 hours and needed a high 
doses of T3 (25 f.l.g T3 per 100 g body weight). Quantitatively, bile acids 
represent the major fate of cholesterol. Cholesterol 7 alpha-hydroxylase 
catalyses the rate limiting reaction in the synthesis of bile acids. The effects of 
T3 on the expression of 7 alpha-hydroxylase gene was studied. It was found 
that a physiological dose of T3 (0.25 !J.g per 100 g body weight) increased 7 
alpha-hydroxylase mRNA very rapidly, consistent with a primary effect on 
the transcription of the encoding gene (75). Because cholesterol is a substrate 
for bile acid synthesis, thyroid hormone thus enhances the utilization of 
cholesterol. The number of LDL-receptors is subject to a negative feedback 
regulation by the intracellular pool of free cholesterol. A decrease in 
intracellular cholesterol levels, will relieve the inhibition and induce 
transcription leading to increased amounts of mRNA for the LDL-receptor. 
This will increase the uptake of circulating LDL-cholesterol by the LDL-
receptor and decrease the concentration of plasma LDL-cholesterol. The 
effects of T3 on the LDL-receptor might partly be explained by this process. 
High (unphysiological) doses T3 for 4 days were needed to stimulate HMG-
CoA reductase mRNA levels (74). The high doses and long duration time 
needed for this reaction to T 3 substitution, suggest that this effect represents a 
compensatory response to cholesterol depletion. 
1.6 IMPACT OF GROWTH HORMONE ON PLASMA LIPO-
PROTEIN CONCENTRATIONS. 
The first studies suggesting that GH is important in the regulation of 
cholesterol metabolism were presented by Byers et al (72,76). The 
administration of GH alone to thyroidectomized rats appeared essentially to be 
as effective as a thyroid extract in preventing the development of hyper-
cholesterolemia. Some years later the involvement of GH in cholesterol 
metabolism in the human situation was shown. In hypercholesterolemic adults 
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supraphysiological doses of GH, acutely lowered the plasma cholesterol 
concentration (77). That GH may decrease plasma cholesterol concentration is 
supported by the finding in patients with acromegaly, which show a lowered 
plasma cholesterol concentration (78). In addition, in adults with GH 
deficiency, Merimee described increased cholesterol levels (79,80). In a long-
term (6 month) experiment it was recently shown that during GH substitution 
in GH deficient adults, the concentration of total plasma cholesterol decreased 
to values lower than in the placebo group (81). On the other hand, growth 
hormone deficient children show either normal (82) or slightly increased (83) 
cholesterol levels. Contradictory effects of GH on serum lipid concentrations 
have been reported in studies in which physiological doses GH were given to 
GH deficient children (82-87). In these children plasma cholesterol has been 
reported to either decrease (84-87) or not to change (82,83). Overall, most 
authors conclude that GH lowers the .concentration of plasma cholesterol in 
man. This decrease in the concentration of plasma cholesterol by GH consists 
of a reduction of both HDL and LDL (85). Different mechanisms may be 
proposed for the decrease in LDL cholesteroL First, a direct stimulating effect 
of GH-activity on the LDL-receptor activity was suggested, as IGF-1 increases 
the number of LDL-receptors and augments the maximal rate of LDL 
internalization and degradation in swine granulosa cells (88). Secondly GH is 
proposed to stimulate the LDL-receptor activity, due to an increased use of 
cholesterol (89). GH was shown to induce an increased activity of 7 alpha-
hydroxylase (90), this enzyme catalyses the rate limiting step in bile acid 
synthesis. 
Although TG levels in GH deficient children and adults are either normal or 
increased (80,82,83), hypertriglyceridemia occurs in acromegaly (78) and 
after GH treatment of healthy controls (91). There are two plausible 
explanations for the induction of an increased TG concentration by GH. The 
first one is a decrease in LPL-activity. In acromegaly patients a decreased 
LPL-activity has been found (92) and GH replacement therapy of GH deficient 
children (93) and healthy volunteers (94) causes a reduction in the LPL-
activity. A decreased LPL-activity will contribute to an increased plasma 
VLDL concentration. Especially VLDLz, suggested to be a VLDL remnant, 
appears to rise (91). This latter effect can also be attributed to a lowered HL-
activity. An other effect of GH on TG metabolism is the induction of an 
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enhanced lipolysis in adipose tissue (95,96), thereby producing increased 
plasma FFA concentrations. Increased FF A concentrations can induce 
triglyceride synthesis in the liver (97), and stimulate VLDL synthesis. 
In humans, the concentration of plasma HDL cholesterol is reported to be 
either reduced or not influenced by GH replacement (85,93). HDL metabolism 
is complex with LPL and HL playing important roles. Both enzymes are found 
to decrease in acromegaly and during treatment with GH of normal adults or 
GH-deficient children (92-94). In hypophysectomized male rats HDL was not 
changed by intermittent GH-treatrnent, mimicking the male secretory pattern, 
while a continuous infusion with GH, mimicking the female secretory pattern, 
induced an increase of the concentration of plasma HDL cholesterol (98) 
suggesting an effect of GH on HDL metabolism. Also in vitro experiments 
support this contribution of GH to HDL metabolism, as a decreased HDL-
receptor activity was shown after incubation of fibroblasts with IGF-I (99). 
1. 7 GROWTH HORMONE AND ATHEROSCLEROSIS. 
Life expectancy is shortened in patients with hypopituitarism. Substitution of 
hydrocortisone, thyroid hormone and sex hormone does not normalize the life 
expectancy which on the average is lowered, because of vascular disorders. 
GH deficiency might explain the premature death from vascular disorders in 
hypopituitarism (100). On the other hand GH-activity has been linked to the 
development of diabetic micro- and macro-angiopathy (101,102). Also 
acromegalic patients (with high GH concentrations) show early atherosclerosis 
(78). The mechanism behind these effects of GH is not precisely known, 
though insulin resistance is thought to add to it. Both deficiency and excess of 
GH appear to be associated with the development of premature vascular 
disease, a better understanding of the contribution of GH in lipid metabolism 
might help to prevent these effects. 
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1.8 SCOPE OF THE THESIS. 
Current data suggest a role for GH in the regulation of lipoprotein 
metabolism. In hypothyroidism not only the secretion of thyroid hormone, but 
also of GH is decreased. Generally the effects on plasma lipids seen in 
hypothyroid individuals are considered to be a consequence of decreased 
thyroid hormone levels. More then twenty years ago evidence was found that 
treatment of hypothyroid rats with GH in supraphysiologic doses affects 
plasma lipid concentrations, but whether a lack of GH (activity) is involved in 
the pathophysiology of lipid metabolism in hypothyroidism can not be 
answered from the present literature. The first aim was to investigate whether 
the changes occurring in lipid metabolism during hypothyroidism, merely 
result from a lack of thyroid hormone or are also attributable to a deficiency 
in GH-activity. In hypothyroid women the relationship between GH-activity 
(lGF-1) and plasma lipoproteins was evaluated (Chapter 2). The effects of a 
physiological dose of GH on lipoprotein concentrations during the 
hypothyroid status were studied in hypothyroid and hypophysectomized rats, 
as reported in Chapter 3. Furthermore, the effects on IGF-I and lipoproteins 
of substitution of hypothyroid rats with varying doses of thyroid hormone 
were studied (Chapter 4). 
The second aim was to investigate the mechanism by which GH can affect lipid 
metabolism, especially during hypothyroidism. The major cause of hyper-
cholesterolemia in hypothyroidism is a decreased LDL catabolism in the liver. 
Hypothyroid rats were treated with GH and the effects of the hypothyroid 
status and GH treatment on liver cell LDL-receptor mRNA, LDL receptor 
expression and HMG-CoA reductase was studied, as described in Chapter 5. 
In Chapter 6 the effects of IGF-1, GH and T3 on the expression and function 
of the LDL-receptor in a human hepatoma derived cell line (HepG2) are 
described. 
Besides the effects of hypothyroidism on LDL metabolism, there are many 
conflicting reports considering the influence of thyroid status on HDL 
metabolism. However, data considering HL-activity, a key enzyme in HDL 
metabolism, uniformly show a decreased activity during hypothyroidism. HL 
is known to be controlled by several hormones, but it is not known whether 
HL-activity is regulated by GH. In Chapter 3 and 4 the effect of the hypo-
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thyroid status and of treatment with GH on HL-activity in liver tissue of hypo-
thyroid rats is described. In Chapter 7 effects of GH replacement in rats on 
HL mRN A levels and HL-activity in liver and in post heparin plasma are 
reported. The effects of GH substitution on serum LDL cholesterol and HL-
activity in post-heparin plasma of patients with GH-deficiency were studied in 
relation to circulating -thyroid hormone concentration as described in 
Chapter 8. 
In the !mal chapter, Chapter 9, the information .obtained in this thesis will be 
discussed. 
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ABSTRACT 
The effect of insulin-like growth factor-I (IGF-I) on the disturbance of lipid 
metabolism during primary hypothyroidism was studied in 12 women with 
primary hypothyroidism. Significant increases in both low-density lipoprotein 
(LDL) cholesterol and intermediate-density lipoprotein (IDL) cholesterol 
were seen. Lipoprotein concentrations reverted to normal after substitution 
with thyroxine (T4) until the euthyroid state was reached. A decrease in IGF-I 
of 65 % (p<0.005) was seen in hypothyroid patients and this was inversely 
correlated (r=- 0.75;p<O.OI) with the concentration of LDL-cholesteroL 
Multivariant regression analysis of LDL-cholesterol against IGF-I and free T 4 
showed that IGF-I determines the concentration of LDL-cholesterol instead of 
free T4. 
Our data suggest that in hypothyroidism IGF-I is a determinant of the 
concentration of LDL-cholesterol. Io addition, hypothyroidism can influence 
plasma lipoprotein metabolism by lowering the activity of the salt-resistant 
lipase (liver lipase). 
INTRODUCTION. 
Hypothyroidism is often accompanied by hyperlipoproteinaemia. Studies of 
the different lipoprotein classes revealed an increase predominantly of low-
density lipoprotein (LDL) cholesterol (Abrams and Grundy, 1981; Muls eta!., 
1985; Rylander and Rosenqvist, 1982; Valdemarsson, 1982). Sometimes, 
however, an increase in plasma concentrations of triglyceride (TG) and 
accumulation of intermediate-density lipoprotein (IDL) cholesterol is also 
found (NikkiUi and Kekki, 1972; Rossner and Rosenqvist, 1974), while only 
minor changes in concentrations of high-density lipoprotein (HDL) cholesterol 
have been reported (Abrams and Grundy, 1981; Valdemarsson, 1982; Lithell 
et aL,l981; Lisch et aL,l982). Lipoprotein changes revert to normal after 
substitution with thyroxine (T 4) (Rylander and Rosenqvist, 1982). The 
mechanism of these changes in lipoprotein metabolism in hypothyroidism is 
not fully understood. It has been suggested that the decreases in lipoprotein 
lipase-activity (LPL) and/or salt resistent liver lipase-activity (HL) are major 
contributors to the typical lipoprotein profiles in patients with thyroid 
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hypofunction (Valdemarsson, 1982), although a decrease of LPL is not always 
found (Abrams et al.,l970; Kraus et al.,l974). In addition, or alternatively, 
impairment of lipoprotein receptor binding may account for the change in 
lipoprotein concentration (Thompson et al.,1981; Scarabottolo et al.,l986). 
Generally the effects on plasma lipid metabolism are considered to be due to 
lowered thyroid hormone levels, but Byers et al. (1970) suggested that, in 
thyroidectomized rats, the chief cause of hypercholesterolaemia might be the 
effect of hypothyroidism on the secretion of growth hormone (GH). The 
administration of GH to these thyroidectomized rats was essentially as 
effective in preventing the occurrence of hypercholesterolaemia as a thyroid 
extract. These data suggested a relationship between hypothyroidism, GH-
activity and hypercholesterolaemia. It is not known in what way GH or insulin-
like growth factor-I (IGF-I) influences lipoprotein metabolism. In the present 
study we analyzed the relationship between IGF-I and various parameters of in 
hypothyroidism. 
MATERIALS AND METHODS. 
Patients. 
The 12 women with primary hypothyroidism who participated in the study 
gave their informed consent. They were aged between 18 and 74 year, and the 
diagnosis was based on clinical grounds in combination with an increased level 
of thyroid-stimulating hormone (TSH) and a subnormal concentration of free 
T 4 (less than 8.5 pmol/1). A group of healthy euthyreoid women aged 21-43 
yr (n=!O) served as controls. Drugs known to influence serum lipids, e.g. beta-
blockers or diuretics, were not administered. None of the patients had clinical 
or biochemical evidence of diabetes mellitus, liver or kidney disease. nor had 
any one of them primary hyperlipoproteinaemia before entering the study. 
Diet was not estimated. The study was approved by the Ethical Committee of 
the University Hospital Dykzigt. Rotterdam, The Netherlands. 
Sample collection 
Two blood samples were obtained between 08.00 and 08.30 h from each 
subject after overnight fasting (I 0 h). The first blood sample was collected on 
ice in tubes containing potassium-EDT A (6.75 mg). After taking the first 
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blood sample a heparin bolus (50 IU/kg bodyweight; Tromboliquine; 
Organon, Oss, The Netherlands) was given i,v, and 20 min later a blood 
sample to measure lipase activities was taken from the contralateral arm and 
put into a tube containing heparin (143 U lithium heparin). Plasma was stored 
at -20 °C until analysis. Blood tests were repeated on the first six patients 
which entered the study after substitution with L-T 4 to euthyroidism. 
Analytical Methods 
Plasma concentrations of triglyceride and cholesterol were determined by 
enzymatic methods (Boehringer-test kit combination). Activities of HL and 
LPL were measured with the immunochemical method previously described 
(Huttunen et al, 1975; Jansen et al., 1980; Nozaki et al., 1986). Enzyme 
activity was expressed in mU. (1 mU represents the release of 1 nmol fatty 
acid from the substrate/min) Lipoprotein fractions were separated after 24 
hour ultracentrifugation of the plasma for 24 h at 200 OOOg at 4 °C using a 
SW-41 rotor in a Beckmann LS-50 ultracentrifuge. Apo E isoforms were 
determined by isoelectric focusing of very low-density lipoprotein (VLDL) 
apolipoproteins as described by Warde! eta!. (1982) using ampholine pH 4-6. 
The concentration of free T 4 and TSH were determined by RIA using SPAC 
ET-FT4 (Byk Sangtec, Dietzenbach, F.R.G.) and RIA-gnost human TSH 
(Hoechst Behring, Marburg, F.R.G.). respectively. The intra assay variation 
for free T4 measurement was 2.5 %. All determinations for free T4 were 
performed in one assay. IGF-I-c was measured by a radio-immunoassay in 
EDT A plasma, using methods described previously (Furlanetto et a1.,1977). A 
commercial kit from Nichols Institute (San Juan Capistrano, California) was 
used. The intra-assay variation in the IGF-I measurement was 7.2 %. 
Measurements for IGF-I were performed in one assay. As IGF-I is known to 
be influenced by the period of fasting and its binding protein is known to have 
a 24-h cyclic variation (Busby et al., 1988), IGF-I samples were collected at a 
fixed time of the day after 10 h fasting. 
Statistical Analysis. 
Data are given as mean ± S.D. Statistical significance of differences was 
evaluated by unpaired or, if appropriate, paired Student's t-test. Correlation 
between different parameters was determined with linear regression analysis 
and multivariant regression analysis. 
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RESULTS 
Hypothyroidism and plasma lipoproteins. 
Hypercholesterolaemia in hypothyroidism was due to a significant increase in 
both LDL-cholesterol and IDL-cholesterol (Table 2.1). A negative linear 
correlation was found between LDL-cholesterol and free T 4 (r=- 0.62, 
p<0.05). There was no significant difference between concentrations in 
hypothyroid and euthyroid patients of total plasma triglycerides, HDL-
cholesterol, VLDL-cholesterol and triglycerides in the various lipoprotein 
fractions. Plasma lipoproteins and IGF-I became normal in patients treated 
with L-T4 until euthyroidism (Table 2.2). A correlation between the type of 
Apo E-polymo:rfism and the type of hyperlipoproteinaemia was not found 
(data not shown). 
Hypothyroidism and LPL activities 
In overt hypothyroidism. HL was decreased to 38 % of the actiVIty in 
euthyreotic state (Table 2.1). HL increased significantly during substitution 
with L-T4 (Table 2.2), while LP- activity did not change. 
Hypothyroidism, concentrations of IGF -I and hypercholesterol-
aemia. 
In most patients with hypothyroidism, IGF-I was decreased and normalized 
after substitution treatment to euthyroidism (Table 2.2). A linear correlation 
between free T4 and IGF-I was found (r = 0.58, p<0.05) (Figure. 2.1). Plasma 
cholesterol and IGF-I showed a negative linear correlation (r = -0.68, 
p<0.05), as did IGF-I and LDL-cholesterol (r = -0.75, p<O.Ol, Figure. 2.1). 
No correlation was seen between IGF-I and IDL-cholesterol, nor between IGF-
I and HL. Multivariant regression analysis of the dependent variable LDL-
cholesterol against IGF-I and free T4 showed a regression coefficient for IGF-
I of -5.25 (p<0.05), while the regression coefficient for free T 4 was only -
0.20 (not significant). This indicates that the correlation of IGF-I to the 
concentration of LDL-cholesterol in hypothyroidism was independent from 
the concentration ofT 4. 
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Table 2.1: Concentrations of lipoproteins, lipases, thyroid hormone and IGF· 
I in 12 patients with primary hypothyroidism and in ten euthyroid 
controls. 
Hypothyroid Euthyroid 
IGF-I (mU/ml) 0.44 ± 0.20 ** 1.27 ± 0.47 
free T4 (pM) 3.17 ± 2.24 ** 12.4 ± 1.90 
Total cholesterol (mM) 7.27 ± 2.24 ** 4.53 ± 0.72 
LDL cholesterol (mM) 4.54 ± 1.69 ** 2.37 ± 0.64 
IDL cholesterol (mM) 0.37 ± 0.19 ** 0.15 ± 0.09 
HDL cholesterol (mM) 1.03 ± 0.33 1.40 ± 0.58 
Triglyceride (mM) 1.38 ± 0.55 1.27 ± 0.47 
Lipoprotein lipase activity (mU/ml) 80±38 118 ± 33 
Liver lipase activity (mU/ml) 108±77 ** 280 ± 11 
Vales are means± S.D. ** P<0.005 compared with controls (Student's t-test) 
Table 2.2: Concentration of lipoproteins, lipases, thyroid hormone and IGF-
I before and after substitution treatment with L-thyroxine of six 
hypothyroid patients. 
Before After 
Treatment Treatment 
IGF-I (mU/ml) 0.40 ± 0.15 ** 1.77 ± 0.24 
free T4 (pM) 2.47 ± 1.99 ** 15.4 ± 4.01 
Total cholesterol (mM) 7.79 ± 1.53 ** 4.90 ± 0.70 
LDL cholesterol (mM) 4.82 ± 1.03 ** 2.84 ± 0.51 
IDL cholesterol (mM) 0.37 ± 0.10 ** 0.26 ± 0.11 
HDL cholesterol (mM) 1.16 ± 0.28 1.02 ± 0.11 
Triglyceride (mM) 1.25 ± 0.34 1.22 ± 0.25 
Lipoprotein lipase activity (mU/ml) 88±29 125 ± 26 
Liver lipase activity (mU/ml) 100 ±77 ** 204 ± 14 
Values are means± S.D. ** P<0.005 compared with controls (Student's t-test) 
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Figure 2.1.: Relationship in hypothyroidism between IGF-I and (a) free thyroxine (f 4) (r = 
0.58, p<0.05), (b) low-density lipoprotein (LDL) cholesterol (r = -0.75, 
p<O.O!). and (c) LDL cholesterol in 12 patients with primary hypothyroidism 
( •) and six patients after being treated with T4 until euthyroid state was reached 
(o). 
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DISCUSSION 
It is not known exactly how hypothyroidism influences lipoprotein 
metabolism. Lipoprotein lipases are thought to play a role in the effect of 
hypothyroidism on lipoprotein changes (V aldemarsson, 1982). In our study 
HL was significantly reduced in hypothyroidism, but LPL was not affected. 
Evidence has been presented that liver lipase may play a role in the 
metabolism of HDL and IDL (Kraus et aL, 1974; Jansen et al., 1980; Nozaki et 
al., 1986). We could not however, find a correlation between HDL-cholesterol 
or IDL-cholesterol and HL It seems unlikely that the lowered HL-activity 
during hypothyroidism is a major determinant of the increase in these 
lipoprotein concentrations.Because we did not observe a correlation between 
lipases and plasma cholesterol or LDL-cholesterol, we were motivated to look 
for an other explanation of the effect of hypothyroidism on LDL metabolism. 
Studies in animal models (Abrams et a!., 1970) and children with 
GH-deficiency (Winter et al., 1979) suggest a relationship berween IGF-I, a 
secondary plasma factor that mediates effects of GH (Daughaday eta!., 1972), 
and lipoprotein metabolism. In hypothyroidism there is evidence for a lack of 
GH-activity (Chernausek et al., 1983) and thyroid hormones are regulators of 
IGF-I levels (Marek et al., 1981). In the present study we found a positive 
linear correlation between IGF-I and free T4 concentrations and a negative 
correlation between IGF-I and plasma cholesterol, mainly LDL-cholesteroL In 
a multivariate regression analysis of LDL-cholesterol, as the dependent 
variable, against IGF-I and free T 4 we found a significant negative correlation 
berween IGF-I and LDL-cholesterol concentrations but not between free T4 
and LDL-cholesteroL Our results suggest that the effect of IGF-I on 
cholesterol metabolism is directly on the LDL-cholesterol metabolism. It has 
recently been shown that IGF-I augments the binding capacity and uptake for 
LDL without altering the LDL-receptor affinity in porcine granulosa cells 
(Veldhuis et aL, 1987). This finding supports the role of IGF-I in LDL 
metabolism. Thompson et aL (1981) demonstrated the existence of a defect of 
receptor-mediated LDL catabolism in hypothyroidism, while Chait et aL 
(1979) showed that tri-iodothyronine stimulates LDL degradation apparently 
by increasing the number of receptors in skin fibroblasts. The increase in 
LDL-cholesterol during hypothyroidism may, therefore, be due to a decrease 
io the LDL receptor-mediated uptake. We conclude that in hypothyroidism 
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IGF-I determines the concentration of LDL independent from free T4. In 
addition hypothyroidism influences lipoprotein metabolism by lowering HL. 
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LIPOPROTEIN METABOLISM IN HYPOTHYROID AND 
HYPOPHYSECTOMIZED RATS. 
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ABSTRACT 
The aim of this study was to evaluate the effect of thyroxine (T 4) and GH 
replacement therapy on serum lipoproteins in rats with primary and secondary 
hypothyroidism and to see whether recovery of GH-activity was associated 
with normalization of serum lipoproteins. In both the primary and secondary 
hypothyroid rats, total cholesterol (TC) was higher than in normal controls, 
due to an increase in low-density lipoprotein cholesterol (LDL-cholesterol) 
and to a lesser extend also in high-density lipoprotein cholesterol 
(HDL-cholesterol). Treatment of hypophysectomized rats with GH induced a 
decrease in concentration of TC, LDL-cholesterol and HDL-cholesteroL The 
effect of GH on HDL-cholesterol was correlated with an increase in hepatic 
lipase (HL)-activity. T 4 replacement therapy of hypophysectomized rats 
normalized LDL-cholesterol, while HDL-cholesterol and HL were unaffected. 
During primary hypothyroidism, T 4 treatment induced GH-activity. increased 
HL activity and reduced the HDL-cholesterol concentration. GH treatment of 
primary hypothyroid rats had a similar influence on the lipid levels and HL as 
in hypophysectomized animals, although the lowering of HDL-cholesterol was 
less prominent. 
These results demonstrate that GH determines serum lipoproteins during both 
primary and secondary hypothyroidism. 
INTRODUCTION 
Hypothyroidism causes pronounced hypercholesterolaemia. In rats this is due 
to an increase in both low-density lipoprotein cholesterol (LDL-cholesterol) 
and high-density lipoprotein cholesterol (HDL-cholesterol) (Dory and 
Roheim, 1981; Gross et aL, 1987). Studies in man revealed an increase in 
predominantly LDL-cho1esterol, while the effect on HDL-cholesterol is still 
controversial (Hoogerbrugge - v .d. Linden et aL, 1989: Chapter 2). The 
mechanisms responsible for these hypothyroidism-related changes in 
lipoprotein levels are not completely understood. During hypothyroidism, 
cholesterol synthesis. estimated by HMG-CoA reductase (the rate-limiting 
enzyme in cholesterol synthesis) activity in the liver, is decreased (Field et aL, 
1986). However, degradation of lipoproteins are retarded secondary to a 
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reduction of the number of LDL receptors, resulting in a rise in 
LDL-cholesterol (Chait et aL, 1979; Thompson et aL, 1981; Scarabottolo et 
aL, 1986). The activity of heparin-releasable salt-resistant lipase from the 
liver (liver lipase activity, HL) is decreased during hypothyroidism (Hiilsmann 
et a!., 1977; Valdemarsson, 1982). A decrease in HL may be responsible for 
an increase in HDL-cholesterol, as HL has a key role in HDL-metabolism 
(Jansen eta!., 1980; Jansen, 1988). 
It is not clear whether these effects on lipoprotein concentrations are due to 
thyroid hormone itself. For instance Byers et al., (1970) suggested that the 
chief cause of hypercholesterolaemia during hypothyroidism is the latter's 
effect on the secretion of growth hormone (GH). They showed that the 
administration of not only thyroid extract, but also of bovine GH (in a supra-
physiologically large dose) to thyroidectomized rats was effective in 
preventing the occurrence of hypercholesterolaemia. Recently we found that 
plasma LDL-cholesterol concentrations in hypothyroid women more strongly 
correlated with insulin like growth factor- I (IGF-I) than with T 4 
(Hoogerbrugge-v.d. Linden et al, 1989; Chapter 2). These results suggest, 
that deficiency of GH is an important factor in the disturbances of plasma 
cholesterol levels in hypothyroid man. 
Although both T 4 and GH can affect lipid metabolism, the specific effects of 
the individual hormones under physiological conditions, are not clear. The 
aim of this study was to investigate the separate effects of GH and T4 on 
cholesterol and lipoprotein metabolism in rats with primary or secondary 
hypothyroidism. 
MATERIALS AND METHODS 
Animals 
Male Wistar rats, 6-7 weeks of age and weighing 185 ± 10 (SD) g, were used 
in all experiments. They were housed at 21 oc on a 12 h cycle of 
light/darkness (lights on at 07.30 h). Vegetarian laboratory chow and drinking 
water were available ad libitum. 
Animal preparation 
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Hypophysectomy 
Hypophysectomy was carried out by the parapharyngeal approach (Thongren 
et aL, 1973). Rats were given a precautionary s.c. injection of 50.000 IU 
Penicillin after hypophysectomy. Hypophysectomy was judged to have been 
complete when, 2 weeks after hypophysectomy, rats showed <2 g weight gaio, 
a serum T4 concentration of less than 1 nmolll and a decrease in testicular 
volume. At autopsy the pituitary fossa was inspected macroscopically for the 
absence of hypophysial tissue. The fossae were empty in all the rats used. A 
corticosterone pellet (C 2505, Sigma, St. Louis, Mo., U.S.A.) weighiog 50 mg 
was implanted s.c., 2 days before administration of T4 and GH. 
Hypothyroidism 
Hypothyroidism was induced by the addition of 0.05 % (w/v) 2-mercapto-l-
methyl-imidazole (Janssen Chimica, 2340 Beerse, Belgium) to the drioking 
water and given during the entire study. The effect of treatment was checked 
by determination ofT 4 concentration io the serum after 14 days of treatment. 
The concentration of T 4 had to be less than 1 nmolll before substitution 
treatment was started. 
Animal treatment procedures 
Hormone administration was started 14 days after operation 
(hypophysectomized rats) or medication (hypothyroid rats). Hormones were 
given for 10 consecutive days by s.c. iojection twice daily at 08.00 and 16.30 
h. L-Thyroxine (Sigma) was dissolved io NaOH (0.1 mol!l) and diluted io 0.9 
% (w/v) NaCL. A daily dose of 2.0 flg T4/lOO g body weight in 0.1 ml was 
used. Treatment with T 4 increased T4 serum concentration (measured 4 h . 
after iojection) from less than 1 nmol/l to 118 ± 29 nmol/l, euthyroid controls 
had a T 4 concentration of 53 ± 12 nmol/1. Tri-iodothyronine (T3) 
concentration in untreated rats was significantly decreased to 0.22 ± 0.37 
nmolll (p < 0.01) and normalized during T4 treatment to 2.03 ± 0.37 nmol/l, 
compared with 1.89 ± 0.17 nmol/l in euthyroid controls. In hypothyroid rats, 
thyrotrophin (TSH) concentrations normalized during treatment with T 4 from 
46.6 ± 11.2 mUll to 0.6 ± 1.0 mUll, compared with 1.2 ± 0.4 mUll in 
euthyroid controls. In hypophysectomized animals TSH decreased below 
detection level. 
For GH studies recombinant human GH (hGH, Norditropin, Novo-Nordisk, 
Denmark; 0.2 IU/100 g body weight) dissolved in 0.05 ml water was used 
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daily. This dose appeared to be physiological from dose-response studies by 
others (Jorgensen, 1987; Skottner et a!., 1987). A combination of these 
hormones was given to a third group. Treatment with GH, alone or in 
combination with T4, did not affect thyroid hormone concentration. Control 
groups of hypophysectomized and hypothyroid rats were given 0.1 ml 0.9 % 
NaCl sc twice daily. Blood was obtained from the orbital plexus the day 
before substitution started. On day 10 of substitution treatment, animals were 
killed by decapitation after 18 h of fasting. Trunk blood was collected. Blood 
sampling and decapitation was performed between 11.30 and 12.30 h. Body 
weights were determined every day at 8.30 h. Body weight gain was defined 
as the increase in body weight between days 2 and 9 of substitution. 
Analytical methods 
Total serum cholesterol and triglycerides were determined by enzymatic 
methods (Boehringer testkit combination, Boehringer, Mannheim, F.R.G.). 
Rat LDL (density (d) = 1.019 - 1.050 g/ml) and rat HDL (d = 1.050 - 1.121 
g/ml) were isolated from pooled serum of two rats by density gradient 
ultracentrifugation (Redgrave et a!., 1975). Lipoprotein fractions were 
separated by ultracentrifugation for 24 h, at 200.000 g using an SW 41 rotor 
in a Beckmann L5-50 ultracentrifuge and isolated by tube slicing. 
Additionally, HDL-cholesterol was determined in serum from individual rats, 
by separating HDL-cholesterol from other lipoproteins by ultracentrifugation 
at l5°C in a 42.2 Ti rotor at d 1.050 g/ml. for 3 h at 223.000 g. Cholesterol 
was measured in the infranatant. Purity of the fractionated HDL was checked 
by determination of Apolipoprotein A1 by a commercially available kit 
(Boehringer). Apolipoprotein A1 was detectable in the HDL and undetectable 
in the LDL fraction (data not shown). 
The lipase activity in the livers was determined in liver homogenates as 
described by Jansen et al. (1980). Briefly, part of the liver was homogenized 
in an ice-cold solution of NaCl (154 mmo!/l, pH 7.40), containing 5 U 
heparin/ml using a polytron tissue homogenizer. Homogenates were 
centrifuged for 5 min at 8000 g at 4 oc and the supernatants, containing more 
than 80 % of all neutral lipase activity, were used. The activity was expressed 
as rnU/rng liver; 1 mU represents the release of l urnol fatty acid from the 
substrate/min. Concentrations of T 4, T 3 and TSH were determined by 
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radioimmunoassay (Visser eta!., 1975) in serum. 
Statistical Methods 
Data are given as mean± S.D. Paired and unpaired Student's t-tests were used 
for comparisons within and between groups. 
RESULTS 
Effects of primary and. secondary hypothyroidism on serum TC. 
The serum concentration of TC was increased (p<O.Ol) by 55 % in 
hypothyroid and by 67 % in hypophysectomized rats when compared with 
controls. This increase in TC was due mainly to an increase in 
LDL-cholesterol, but also in HDL-cholesterol concentration (Table 3.1 and 
3.2). LDL-cholesterol was increased (p<O.Ol) by 251 % in hypothyroid and 
by 300 % in hypophysectomized rats; HDL-cholesterol was increased (p<O.Ol) 
by 31 % and 25 % respectively. 
Effects of hormonal treatment in hypophysectomized rats on 
cholesterol and lipoproteins. 
Treatment with either T4 or GH was effective in reducing TC in serum from 
hypophysectomized rats. The reduction in serum TC achieved by treatment 
with T4 was significantly greater (p< 0.05) than with GH. Combined treatment 
with T4 and GH normalized TC. 
Treatment of hypophysectomized rats with T 4 induced a decrease of 75 % 
(p<0.05) in the LDL-cholesterol concentration to normal. T 4 did not influence 
HDL-cholesterol concentration nor HL (Table 3.1). Treatment with GH 
reduced LDL-cholesterol levels by 30 % (p<0.05), this reduction being less 
than that after treatment with T4. In contrast to T4, GH stimulated HL and 
caused a decrease in HDL-cholesterol. HDL-cholesterol measured in sera of 
individual rats, showed an HDL-cholesterol concentration of 2.04 ± 0.24 
mmol/1 in untreated and 1.67 ± 0.18 mmol/1 in GH treated rats (p<O.Ol). 
Combined treatment with both T4 and GH normalized lipid and lipoprotein 
concentrations in hypophysectomized animals. 
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Table 3.1: Effect of substitution treatment with thyroxine (T4), GH, or a 
combination of the two hormones in hypophysectomized (HPX) 
rats. 
Treatment (N) TC 
(mM) 
LDL-c 
(mM) 
HDLc 
(mM) 
HL BWG 
(mU/mg liver) (g) 
Control 
HPX 
HPX+T4 
HPX+GH 
(12) 2.40 ± 0.28* 0.35 ± 0.06* 1.53 ± 0.16* 1.18 ± 0.26* 34.6 ± 6.7* 
(13) 4.01 ± 0.37 1.42 ± 0.36 1.92 ± 0.32 0.49 ± 0.12 -5.6 ± 4.2 
(13) 2.67 ± 0.41 * 0.35 ± 0.26* 1.87 ± 0.48 0.55 ± 0.12 -6.2 ± 4.8 
(16) 3.02 ± 0.32* 1.00 ± 0.16* 1.64 ± 0.17 0.75 ± 0.14* 16.8 ± 3.9* 
HPX+T •+GH(I6) 2.49 ± 0.32* 0.38 ± 0.07* 1.55 ± 0.21* 0.90 ± 0.13* 16.4 ± 5.9* 
Data are means± S.D. for the numbers of rats in parentheses: for determination of high-
density lipoprotein cholesterol (HDL-c) and low-density lipoprotein cholesterol (LDL-
c) pooled sera of two rats were used. 
* P < 0.05 compared to hypophysectomized rats (Student's t-test). 
Table 3.2: Effect of substitution treatment with thyroxine (T 4), GH, or a 
combination of the two hormones in hypothyroid rats (HTH). 
Treatment (N) TC LDL-c HDLc HL BWG 
(mM) (mM) (mM) (mU!mg liver) (g) 
HTH (12) 3.71 ± 0.48 1.23 ± 0.28 2.00 ± 0.49 0.56 ± 0.12 . 2.1 ±4.4 
HTH+T4 (16) 2.51 ± 0.30* 0.36 ± 0.07* 1.69 ± 0.32 0.87 ± 0.16* 14.8 ± 7.4* 
HTH+GH (16) 3.37 ± 0.27* 1.02 ± 0.22 1.85 ± 0.24 0.81 ± 0.16* 9.4 ± 3.2* 
HTH+T4+GH 16) 2.20 ± 0.19* 0.15 ± 0.08* 1.58 ± 0.09* 1.00 ± 0.12* 13.3 ± 5.4* 
Data are means± S.D. for the numbers of rats in parentheses; for determination of high-
density lipoprotein cholesterol (HDL-c) and low-density lipoprotein cholesterol (LDL-
c) pooled sera of two rats were used. 
* P < 0.05 compared with values in hypothyroid rats (Student's !·test) 
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Effects of hormonal treatment of hypothyroid rats on cholesterol 
and lipoproteins. 
Admioistration of GH to hypothyroid rats produced the same changes io lipid 
and lipoprotein concentrations as observed io hypophysectomized animals 
(Table 3.2). In contrast to its effects io hypophysectomized rats, T4 treatment 
of hypothyroid rats induced a decrease io HDL-cholesterol and an increase in 
HL. This remarkable increase in HL was correlated to an iocrease io body 
weight (r = 0.67, p<O.OOl). In T4 treated hypophysectomized animals, no 
body weight gain was seen (Table 3.1). 
DISCUSSION 
The present study iodicates that a physiological dose of GH can reduce 
hypercholesterolaemia in hypothyroid rats. A cholesterol-decreasing effect of 
GH was known from studies in GH-deficient children treated with GH 
(Blackett et a!., 1982), and in patients with Acromegaly (NikkiHi and 
Pelkanen, 1975). This study shows that the cholesterol-decreasiog effect of GH 
is maioly due to a decrease in LDL-cholesterol, although HDL-cholesterol is 
also lowered. Treatment of hypothyroid and hypophysectomized rats with GH 
had a stimulating effect on HL, thereby probably reducing HDL-cholesterol 
concentrations. In contrast to GH, treatment of hypophysectomized rats with 
T 4 alone did not affect HL, nor HDL-cholesterol, but produced an additional 
effect on HL when in combination with GH. Treatment of hypothyroid rats 
with T4, on the other hand, stimulated HL and lowered HDL-cholesterol, 
which suggests induction of GH-activity by T4. For estimation of GH-activity 
we measured body weight gaio, a known bioassay (Groesbeck and Parlow, 
1987). Body weight fell during primary and secondary hypothyroidism. In 
hypothyroid rats body weight increased during treatment with GH and more 
so with T4, indicatiog an (at least partial) restoration of GH-activity during T 4 
treatment in hypothyroid animals. In contrast, hypophysectomized animals did 
not show an iocrease io body weight after treatment with T4. 
The suggested decrease in GH-activity during primary hypothyroidism is 
shown by others too, e.g. the synthesis of GH in the pituitary gland is 
decreased in primary hypothyroidism (Evans et a!., 1982; Casanova et aL, 
1985; Wood et al., 1987). resulting io decreased GH content of the pituitary 
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(Stachura, 1986) and decreased secretion of GH during stimulation tests (Root 
et aL, 1985; Katakami et aL, 1986). Furthermore, the normal pulsatile pattern 
of GH secretion is lost during hypothyroidism. Both production and secretion 
of GH can be restored by administering T 4 to hypothyroid rats (Martin et aL, 
1985; Katakami et aL, 1986). When drawing conclusions from data on the 
effects of thyroid hormones on hypothyroid rats, it is important to take 
account of the fact that the secretion not only of thyroid hormone, but also of 
GH is low during primary hypothyroidism, while both hormones will be 
restored by the administration of T 4-
The main effect of T4 on TC in hypothyroid and hypophysectomized is a 
decrease in the concentration of LDL-cholesteroL Although both T4 and GH 
are able to lower the LDL-cholesterol concentration, the effect ofT 4 is more 
potent, suggesting a role of thyroid hormone itself in LDL metabolism. A 
mediating role of GH in LDL-cholesterol metabolism in hypothyroid rats is 
suggested, as combined treatment had an additive effect in the decrease of 
LDL-cholesterol in these animals. The effects of thyroid hormone on LDL are 
known from in vitro experiments; T 3 was shown to promote the binding of 
LDL to its receptor in fibroblasts (Chait et aL, 1979). More recently, it was 
shown that insulin like growth factor-I (IGF-n has a positive effect on the 
number of LDL receptors in granulosa cells (Veldhuis eta!., 1987), while we 
found that LDL-cholesterol levels are related more to the concentration of 
IGF-1, than to that of thyroid hormone in hypothyroid women (N. 
Hoogerbrugge-v.d.Linden et aL, 1989; Chapter 2). 
The present study in hypophysectomized rats shows that both T4 and GH 
decrease LDL-cholesterol, while only GH and not T 4 decreases 
HDL-cholesterol by an increase in HL 
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Chapter 4 
INTERACTION OF GROWTH HORMONE ACTIVITY AND 
THYROID HORMONE IN THE LIPOPROTEIN METABOLISM OF 
HYPOTHYROID RATS. 
N. Hoogerbrugge, H. Jansen, N.M.H. Wouters, P. Uitterlinden and 
J.C. Birkenhager. 
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ABSTRACT 
In hypothyroid rats hypercholesterolemia is present, due to an increase in both 
low density lipoprotein (LDL)-cholesterol and high density lipoprotein (HDL)-
cholesterol. The activity of hepatic lipase (HL), an important enzyme in HDL 
metabolism, is decreased. LDL-cholesterol and HDL-cholesterol can be 
reduced and HL-activity stimulated by substitution with growth hormone 
(GH). In the present work the role of GH in the disturbed lipid metabolism 
during hypothyroidism was studied. 
In a severely hypothyroid state in methimazole treated rats (TSH>46 mUll), 
the IGF-I concentration was decreased by 51%. Treatment with a low daily 
dose ofT 4 (0.25 J.!g/100g body weight (BW)), did not restore euthyroidism, 
but normalized IGF-I levels. During treatment with this low dose T 4 , the LDL-
cholesterol concentration was partially corrected, (-33%), but the HDL-
cholesterol level and HL-activity did not change. When higher substitution 
doses of T4 were given, LDL-cholesterol concentration decreased further and 
HL-activity increased dose dependently. 
In hypophysectomized rats, substitution with T4 (2 J.!g/100g BW per day) 
restored the euthyroid state, normalized the LDL-cholesterol concentration, 
but did not affect HL-activity. 
Thus GH and/or IGF-I partly reduced LDL-cholesterol and HDL-cholesterol 
and increased HL-activity, while thyroid hormone stimulated HL-activity only 
in the presence of GH-activity. The LDL-cholesterol concentration is 
decreased by both hormones independently, with thyroid hormone having 
greatest effects. 
INTRODUCTION 
Among the most prominent metabolic consequences of hypothyroidism is 
hypercholesterolemia (Epstein and Lande, 1922; Masom et al., Hunt and 
Hurxthal, 1930; Peters and Man, 1950; Valdemarsson, 1983; Heimberg et aL 
1985). A number of reports have demonstrated that both the low density 
lipoprotein (LDL)-cholesterol and the high density lipoprotein 
(HDL)-cholesterol concentrations are increased in hypothyroid rats (Dory and 
Roheim, 1981; Gross et al., 1987), while hepatic lipase (HL)-activity, an 
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important enzyme in HDL metabolism, is decreased (Kuusi et a!., 1988; 
Murase and U chimura, 1980). The lipoprotein pattern reverts to normal after 
substitution with thyroxine (T4) (Kuusi et a!., !988). 
Thyroid hormone is thought to be responsible for these changes in lipid 
concentrations, but during hypothyroidism growth hormone (GH)-activity is 
also decreased (Chernausek and Turner, 1989; Katakami et a!., 1986; 
Iwatsubes et a!., 1967), indicating a possible role for GH-deficiency in the 
hypercholesterolemia as well. GH is known to decrease the serum cholesterol 
concentration in man and rats (Friedman et a!., Elek, 1970; Friedman et a!., 
1974; Nikkila and Pelkonen, 1975). In hypothyroid women we found that the 
LDL-cholesterol concentration was more strongly correlated to Insulin-like 
Growth Factor I (IGF-I) levels than to T4 (Hoogerbrugge-vd Linden et a!., 
1989; Chapter 2). Hypothyroid rats develop hypercholesterolemia due to an 
increase in both LDL- and HDL-cholesterol, while in man 
hypercholesterolemia is predominantly a result of increased LDL-cholesterol. 
Hypophysectomized rats substituted with GH showed a decrease of both HDL-
and LDL-cholesterol concentration (Hoogerbrugge-v.d.Linden et a!., 1990; 
Chapter 3). Normalization of the levels of these lipoproteins was achieved 
when both GH and T 4 were substituted. 
In the present study we have further investigated the relationship between GH, 
thyroid hormone and lipid metabolism of hypothyroid rats. 
MATERIALS AND METHODS 
Animals and treatments. 
Animals 
Male pubertal Wistar rats, 6-7 weeks of age and weighing 185 ± 10 (SD) g, 
were used in all experiments. They were housed at 21 °C on a 12 h cycle of 
light/darkness (lights on at 07.30 h). Chow and drinking water were available 
ad libitum. Vegetarian chow (containing a mixture of grains, herbs and seeds) 
was obtained from Puyk (Rabbit chow, Holland Diervoeders, Hilversum, The 
Netherlands). 
Induction of hypothyroidism 
Hypothyroidism was induced by the addition of 0.05 % (w/v) 2-mercapto-1-
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methyl-imidazole (Janssen Chimica, 2340 Beerse, Belgium) to the drinking 
water and given during the entire study. 
Hypophysectomv 
Hypophysectomy was carried out by the parapharyngeal approach (Thongren 
et al., 1973). Rats were given a precautionary s.c. injection of 50.000 IU Peni-
cillin after hypophysectomy. Hypophysectomy was judged to be complete 
when, 2 weeks after hypophysectomy, rats showed <2 g weight gain, a serum 
T 4 concentration of less than 1 nmol/1 and a decrease in testicular volume. A 
corticosterone pellet (C 2505, Sigma, St. Louis, Mo., U.S.A.) weighing 50 mg 
was implanted s.c., 2 days before administration of hormones. 
Administration of hormones 
Hormone administration was started 14 days after medication (hypothyroid 
rats) or operation (hypophysectomized rats). Hormones were given twice daily 
for 10 consecutive days by s.c. injection. L-Thyroxine (Sigma) was dissolved 
in NaOH (0.1 mol/!) and diluted in 0.9 % (w/v) NaCL. The daily dose of T4 
used varied between 0.25 - 2 !lg/IOOg BW. Recombinant human GH (hGH, 
Norditropin, Novo-Nordisk, Denmark) was given subcutaneously in a daily 
dose of 0.2 IU/100 g BW. After 10 days of substitution, animals were killed 
by decapitation after 18 h of fasting. Trunk blood was collected. Blood 
sampling and decapitation was performed between 11.30 and 12.30 h. Body 
weights were determined every day at 8.30 h. Body weight gain (BWG) was 
defmed as the increase in body weight between days 2 and 9 of substitution. 
Analytical methods 
Total serum cholesterol and triglycerides were determined by enzymatic 
method (Boehringer testkit combination, Boehringer, Mannheim, F.R.G.). Rat 
LDL (density (d)= 1.019- 1.050 g/ml) and rat HDL (d = 1.050- 1.121 g/ml) 
were isolated by density gradient ultracentrifugation (Redgrave, et. a!.. 1975). 
The HL-activity was determined in liver homogenates as described by Jansen 
eta! (1980). The activity was expressed as mU/mg liver: I mU represents the 
release of I nmol fatty acid from the substrate/min. 
Concentrations of T4 and T3 were determined by radioimmunoassay (Visser et 
al., 1975), rat-TSH was determined by RIA using materials supplied by the 
NIDDK. TSH RP-2 was used as standard as described by Rondeel et al. 
(1988). 
The rat IGF-I concentration was determined by radioimmunoassay, using a 
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test kit (Nichols institute diagnostics, San Juan Capistrano, CA 92675). 
Statistical Methods 
All data are expressed as mean ± S.D. Student's t-tests were used for 
comparisons between groups. The statistical significance of the differences 
within groups was determined using analysis of variance (ANOV A). 
RESULTS 
Effects of vegetarian food on lipids and lipoproteins in the rat. 
In all experiments the rats were fed a vegetarian diet. In a pilot study using 
normal lab chow, suspicion was raised for the presence of thyroid hormone in 
this chow. Methimazole treatment resulted in T 4 concentrations not lower than 
12 ± 5 nM (Table 4.1). In rats fed a vegetarian lab chow, T4 levels were 
significantly lower (Table 4.1 ). 
Compared to the normally fed rats, the vegetarian fed rats showed an increase 
in serum cholesterol concentration of approximately 50 % (p<O.Ol, Table 
4.1). due to an increase in both LDL-cholesterol and HDL-cholesterol. The 
LDL-cholesterol concentration in normally fed- and in vegetarian fed animals, 
was 0.25 ± 0.03 mM and 0.35 ± 0.05 mM (p<O.Ol), respectively, and HDL-
cholesterol 0.91 ± 0.09 mM and 1.53 ± 0.16 mM (p<O.Ol), respectively. Total 
triglycerides (TG) and very-low density lipoprotein (VLDL)-TG were highly 
variable (1.20 ± 0.24 mM and 0.68 ± 0.14 mM respectively). 
Besides differences in plasma lipids also the IGF-I concentration varied in rats 
fed the normal- or the vegetarian-chow. The IGF-I concentration in 
vegetarian fed hypothyroid rats was decreased with 50 % (p<0.01) as 
compared to euthyroid rats (Table 4.1). 
Severity of hypothyroidism and its effects on IGF-I and lipids. 
To induce differences in severity of hypothyroidism, groups of hypothyroid 
rats were treated with varying amounts ofT 4 (0, 0.25, 0.5, 0.75, 1.0, 1.5 
).lg/100 g body weight per day). The severity of hypothyroidism was checked 
by the concentration of T3, T4 and TSH in serum (Table 4.2). With respect to 
the TSH concentration, normalization was achieved using a daily dose of 0.75-
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Figure 4.1: The effect of treatment of hypothyroid rats with different doses of thyroxine 
(T4) on plasma insulin-like growth factor-! (IGF-I. squares. closed line) and 
body weight gain (BWG. circles. dotted line). IGF-I concentration of controls 
are indicated by a black square. Each group represents the data of 6 rats. Data 
are presented as mean± SD. 
1.0 J.lg T4/100g. The lowest daily dose of T4 (0.25 J.Lg/lOOg BW) did not 
restore euthyroidism (Table 4.2), but normalized IGF-I concentration (Figure 
4.1). A further increase in T4 dose did not result in higher IGF-I levels. The 
increase in IGF-I concentration during treatment with T 4 was paralleled by an 
increased body weight gain (BWG, Figure 4.1), another parameter for GH-
activity .The lowest dose ofT 4 (0.25 J.lg/lOOg BW) led to a decrease in the 
LDL-cholesterol concentration from 1.06 ± 0.11 roM to 0.71 ± 0.06 roM 
(p<O.Ol). The LDL-cholesterol concentration in the group of animals treated 
with the highest dose T 4 ( 1.5 J.Lg/1 OOg BW) was decreased as compared to the 
group treated with the lowest dose of T 4 (0.25 J.Lg/l OOg BW), to a con-
centration of 0.49 ± 0.04 roM (p<0.05, Figure 4.2). The HDL-cholesterol-
concentration was affected by T 4 only in the group treated with 1.5 J.Lg T 4/100 
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Figure 4.2: The effect of treatment of hypothyroid rats with different doses of thyroxine 
(T 4). on low density lipoprotein cholesterol (LDLc, closed line) and hepatic 
lipase (HL, dotted line). Values are means± SD. Each group represents the data 
of 6 rats~ for determination pooled sera of two rats were used. Data 
significantly different from the group treated with 0.25 Jlg/lOOg BW are marked 
with an asterisk (p<0.05). 
g BW, in this group HDL-cholesterollevels normalized from 1.78 ± 0.01 to 
!.51 ± 0.06 mM (p<O.O 1 ), respectively. The HL-activity was decreased during 
hypothyroidism, as compared to the euthyroid state (0.50 ± 0.04 mU/mg liver 
verses 1.36 ± 0.13 mU/mg liver (p<O.OI), respectively). After treatment with 
1.5 ).!g T4/IOO g BW, HL-activity increased to 0.77 ± 0.06 mU/mg liver 
(p<0.05). 
Effects of treatment with T 4 and GH on lipoproteins in hypo-
physectomized rats. 
Treatment of hypophysectomized rats with T4 in a daily dose of 2).!g/100g 
BW, led to a decrease of 75 % (p < 0.05) in the LDL-cholesterol concentration 
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Table 4.1: The effects of normal and vegetarian chow on cholesterol, 
thyroxine (T 4 ) and Insulin like Growth Factor I (IGF -I) in 
euthyroid and hypothyroid rats. 
Normal Lab Chow 
n 
cholesterol (mM) 
T4 (nM) 
IGF-l (U/rnl) 
Vegetarian Chow 
n 
cholesterol (mM) 
T4 (nM) 
IGF-I (U/rnl) 
Controls 
(6) 
1.7 ± 0.08 
23 ±5 
5.28 ± 0.40 
(6) 
2.5 ± 0.3 
40 ±8 
3.02 ± 0.47 
Hypothyroids 
(12) 
2.5 ± 0.3 * 
12 ±5 * 
4.86 ± 0.55 
(6) 
3.5 ± 0.3 * 
4 ±5 * 
1.49 ± 0.18 * 
*Significantly different compared to controls in a Student's T-test (p<O.Ol) 
Table 4.2: The effect of treatment with different doses of thyroxine (T 4 ) of 
hypothyroid rats for 10 days on serum T4, triiodothyronine (T3) 
and thyroid stimulating hormone (TSH). 
Substitution 
DoseT4 T4 T3 TSH 
~g/IOOg/day nM nM mUll 
Controls 
0 40± 8 1.89 ± 0.17 1.2 ± 0.4 
Hypothyroids 
0 4 ± 5* 0.22 ± 0.14* 46.6 ± 11.2* 
0.25 41 ± 8 1.03 ± 0.53* 21.2± 9.9* 
0.5 82 ± 12* 1.22 ± 0.21* 5.7± 1.6* 
0.75 102±11* 1.27 ± 0.16* 2.0± 0.9 
I 128 ± 9* 1.50 ± 0.21* 0.7 ± 0.3 * 
1.5 140 ± 36* 2.03 ± 0.37 0.6 ± 0.1 * 
Each group represents the data of 6 rats. Data are presented as mean± SD. 
*Significantly different from controls in ANOVA (p<O.Ol). 
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Figure 4.3: Effects of substitution treatment with thyroxine (f 4). growth hormone (GH). or 
a combination of the two hormones in hypophysectontized (hypox) rats on, A: 
low density lipoprotein (LDL) cholesterol. B: high density lipoprotein (HDL) 
cholesterol (open bars) and hepatic lipase (HL)-activity (closed bars). Values 
are means ± SD. for the numbers of rats in parentheses; for determination of 
HDL) cholesterol and LDL cholesterol pooled sera of two rats were used. Data 
significantly different from the hypophysectontized rats are marked with an 
asterisk (p<0.05). 
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(Figure 4.3), but did not influence the HDL-cholesterol concentration nor HL-
activity (Figure 4.3). Treatment with GH reduced LDL-cholesterol levels by 
30 % (p < 0.05). This reduction was less than with T 4 (p<0.05). In contrast to 
T 4, GH stimulated HL-activity (p<0.05) and caused a decrease in HDL-
cholesterol (n.s.). Combined treatment with both T 4 and GH normalized HDL-
cholesterol concentrations and induced a furtber increase in HL-activity with 
20 % (p<O.Ol), compared to GH treated hypophysectomized rats (Figure 
4.3). Administration of GH to hypothyroid rats produced the same changes in 
lipid and lipoprotein concentrations as observed in hypophysectomized animals 
(data not shown). The effects of hormonal substitution treatment of 
hypophysectomized rats on body weight are given in Figure 4.4. 
DISCUSSION 
The effects of GH and thyroid hormone on LDL- and HDL-cholesterol 
concentrations were studied. We have previously found that LDL- and HDL-
cholesterol in the rat are both affected by GH and thyroid hormone 
(Hoogerbrugge-v.d.Linden et al, 1990; Chapter 3). The thyroid hormone 
status influences the GH-activity, represented by the IGF-I concentration. As 
seen by others (Chernausek et al., 1983; Valcavi et al., 1987), we found that 
during hypothyroidism, IGF-I is greatly diminished and returned to control 
values after thyroid hormone substitution. The IGF-I levels we measured, are 
in accord with the findings of Skottner et al (1987). In the present study 
hypothyroid rats were treated with different amounts ofT 4· The lowest dose 
of T4 (0.25 J.l.g/lOOg) increased T3 and decreased TSH concentration 
considerably. Larger doses of T 4 led to a furtber response in these variables. 
GH-activity, as reflected in the IGF-I concentration and the body weight 
gain, was increased to control values at the lowest substitution dose ofT 4 and 
did not increase furtber at higher doses. 
The LDL-cholesterol concentration was decreased during the thyroid hormone 
substitution and showed the same biphasic response as T3 and TSH. From these 
data it can not be concluded whether the first fast phase in the lowering of 
LDL-cholesterol is due to the increase in thyroid hormone or (and) IGF-I. 
However, since during the second slower phase IGF-I remains constant, it 
seems that the decrease in LDL-cholesterol during this phase is due to the 
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Figure 4.4: Effects of substitution treatment with thyroxine (T 4 ), growth hormone (GH), or 
a combination of the two hormones in hypophysectomized (hypox) rats on 
body weight. Each point represents the mean of 12 rats. 
increase in thyroid hormone rather than to IGF-I. From these data it seems, 
that in the rat the LDL- cholesterol concentration is rather governed by 
thyroid hormone- than by the growth hormone-activity. To elaborate on this 
finding further, hypophysectomized rats were treated with T4. Under 
thiscondition the thyroid hormone status is normalized, while IGF-I is only 
marginally affected (1.26 ± 0.30 U/ml versus 0.76 ± 0.14 U/ml). Body weight 
is not influenced during treatment with T4 suggesting that GH activity is 
negligible. T 4 treatment led to a complete normalization of LDL-cholesterol, 
again indicating the dependency of LDL-cholesterol on thyroid hormone. 
However, GH substitution of the hypophysectomized rats lowered LDL-
cholesterol also. This is in line with studies in humans, were we showed the 
plasma LDL-cholesterol during hypothyroidism is strongly related to IGF-I 
concentration (Hoogerbrugge-v.d.Linden eta!., 1989; Chapter 2). Plasma 
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Table 4.3: Effects of substitution treatment with thyroxine (T 4 ), growth 
hormone (GH), or a combination of the two hormones in 
hypophysectomized (hypox) rats. 
n LDLc HDLc HL activity 
mM mM mU/mg liver 
Control (12) 0.35 ± 0.06* 1.53 ± 0.16* 1.18 ± 0.26* 
Hypox (13) 1.42 ± 0.36 1.92 ± 0.32 0.49 ± 0.12 
Hypox +T4 (13) 0.35 ± 0.26* 1.87 ± 0.48 0.55 ± 0.12 
Hypox +GH (16) 1.00 ± 0.16* 1.64± 0.17 0.75 ± 0.14* 
Hypox +T4+GH (16) 0.38 ± 0.07* 1.55 ± 0.21 * 0.90 ± 0.13* 
Values are means± SD. for the numbers of rats in parentheses; for determination of 
high density lipoprotein cholesterol (HDLc) and low density lipoprotein cholesterol 
(LDLc) pooled sera of two rats were used. HL is hepatic lipase. 
* Significantly different from hypophysectomized rats in a Smdent"s t-test (p<0.05). 
LDL-cholesterol concentration is determined mainly by its rate of removal, 
which is dependent on the LDL-receptor activity (Goldstein and Brown, 
1986). Indeed in hypothyroidism LDL catabolism is decreased (Thompson et 
al., 1981). Recently we described that substitution with GH of hypothyroid 
rats stimulates LDL-receptor mRNA levels and activity of liver cells 
(Hoogerbrugge et al., Chapter 5) 
HDL-cholesterollevels are largely dependent on HL activity, an enzyme which 
plays a key role in the metabolism of HDL (Jansen et a!., 1980). Under all 
conditions studied in this experiment, both variables were strongly inversely 
correlated. HL-activity and the related HDL-cholesterol concentration showed 
a completely different picture in the response to thyroid hormone and GH. In 
hypophysectomized rats substitution with T 4 had no effect on either variable, 
indicating that the hypothyroidism as such was not responsible for the lowered 
HL activity in hypophysectomized rats. Treatment with GH increased the 
lipase activity significantly. But in the presence of both GH and thyroid 
hormone the activity was further increased to control values. Therefore, GH 
and/or IGF-I seems to be a permissive factor in the influence of thyroid 
hormone on HL. In hypothyroid rats thyroid hormone substitution led to an 
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increase in HL actlvtty which was not directly related to either thyroid 
hormone or IGF-I concentrations. Probably the initial increase in IGF-I 
triggers the increase in HL which is then further enhanced by the increase in 
thyroid hormone. HDL-cholesterol followed inversely the HL-activity 
suggesting a causal relationship, which is feasible in the light of the proposed 
function of HL in the catabolism of HDL-cholesterol. 
To obtain a truly hypothyroid state necessary for a deprivation of GH-activity, 
methimazol treated rats were deprived from exogenous thyroid hormone. As 
contamination of laboratory chow with thyroid hormone was suspected, rats 
were fed a vegetarian diet. Compared to the levels in control rats fed the usual 
laboratory chow, the vegetarian fed control rats showed an increase in the 
concentration of both LDL- and HDL-cholesterol (data not shown). Hypo-
thyroidism increased these lipoproteins both in the vegetarian and in the 
control-fed animals. 
In these studies we showed that GH and thyroid hormone are both involved in 
the regulation of two important lipoproteins in the rat, LDL and HDL. While 
thyroid hormone appeared to be of primary importance in the regulation of 
LDL-cholesterol, GH has a distinct additional LDL-cholesterol decreasing 
effect. In the regulation of HDL cholesterol, HL-activity appears to be of 
major importance. For the activity of HL, GH was shown to be a permissive 
factor, in the presence of which thyroid hormone can stimulate the activity. 
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Chapter 5 
GROWTH HORMONE ENHANCES mRNA AND ACTIVITY OF 
THE LOW DENSITY LIPOPROTEIN-RECEPTOR IN THE LIVER 
OF HYPOTHYROID RATS. 
N. Hoogerbrugge, H. Jansen, B. Staels, M.J.E. Seip, J. Auwerx and 
J.C. Birkenhager. 
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ABSTRACT 
In hypothyroid rats hypercholesterolemia, partially due to a decreased low-
density lipoprotein-receptor (LDL-R) activity, is present. This hypercho-
lesterolemia can be corrected to some extent by substitution of growth 
hormone (GH). In the present study the mechanism of this GH mediated effect 
was investigated. 
Liver LDL-R mRNA levels and LDL-R concentrations in hypothyroid rats 
were diminished by 69% and 33% respectively. Substitution treatment with 
GH, to activity levels seen in euthyroid controls (as determined by plasma IGF-
1 concentrations and restoration of growth), led to a normalization of both 
LDL-R mRNA and LDL-R activity. 
In hypothyroids, HMG-CoA reductase activity was decreased by 64%. This 
activity rose after substitution of GH, excluding an indirect effect of GH on 
LDL-R via a decreased HMG-CoA reductase activity. 
These data show that GH modulates hepatic LDL-R activity, by regulating 
LDL-R gene expression. These observations demonstrate the importance of 
GH in cholesterol homeostasis. 
INTRODUCTION 
The regulation of cholesterol metabolism is multifactorial, diet and hormones 
playing major roles. Growth hormone (GH) has a profound but not yet 
completely understood effect on cholesterol metabolism: In 
hypercholesterolemic adults, supraphysiological doses of GH lower serum 
cholesterol (Friedman et a!., 1974) and GH over production, as found in 
acromegaly, is accompanied by low serum cholesterol levels (NikkiUi and 
Pelkonen, 1975). Also in primary hypothyroidism, which is accompanied by 
GH deficiency (Katakami et al., 1986; Wood et al., 1987), 
hypercholesterolemia is present (Walton et al .. 1965; Dory and Roheim. 1981; 
Sykes et a!.. 1981; Gross et a!., 1987). We recently reported that in 
hypothyroid patients the elevated low-density lipoprotein (LDL) cholesterol 
concentrations are more strongly related to the IGF-I than to free thyroxine 
concentration (Hoogerbrugge-v .d. Linden et al., 1989; Chapter 2), indicating 
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the relevance of GH for cholesterol metabolism. In addition. it was found that 
the serum cholesterol concentrations in hypothyroid rats decreased upon 
substitution with GH (Byers et al., 1970; Hoogerbrugge-v.d.Linden et al., 
1990; Chapter 3 ). The hypercholesterolemia in hypothyroidism is partially 
caused by an increase in LDL cholesterol, which is probably due to a reduced 
catabolic rate of this lipoprotein via the LDL receptor (LDL-R) (Thompson et 
al., 1981; Scarabottola et a!., 1986). It has been demonstrated that the low 
LDL-R expression in the hypothyroid state can be stimulated by thyroid 
hormone (TH) (Chait et al., 1979). This effect of TH on LDL-R expression 
may either be direct or indirect via a TH-induced increase in GH synthesis and 
secretion (Martinet al., 1985; Katakami et al., 1986). The effect of treatment 
of hypothyroidism with TH on LDL-R can also be secondary to a lowering of 
the intracellular cholesterol concentration, as the number of LDL-R is subject 
to a negative regulation by this concentration: when this concentration falls, 
increased numbers of LDL-R are produced. Therefore we determined the 
effect of GH on the activity of hydroxy-methylglutaryl-Coenzyme-A (HMG-
CoA) reductase, the rate limiting enzyme in cholesterol synthesis. 
The present study was designed to examine the role of GH in the regulation of 
cholesterol metabolism during hypothyroidism in rats. 
MATERIALS AND METHODS. 
Animals and treatments. 
Animals 
Pubertal male Wistar rats weighing 185 ± 10 (SD) gram were used in all 
experiments. They were housed at 21 °C on a 12 hour light cycle. Vegetarian 
laboratory chow (free from thyroid hormone) and drinking water were 
available ad libitum. 
Induction of hypothyroidism 
Hypothyroidism was induced by the addition of 0.05 % (w/v) 2-mercapto-1-
methyl-imidazole (Janssen Chimica, 2340 Beerse Belgium) to the drinking 
water during the entire study period of 24 days. Serum T 4 concentrations 
were determined after 14 days of treatment. If T 4 was less than 1 nmol/1, 
administration of GH was started. 
Administration of GH 
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hGH (Norditropin) was a generous gift from Novo-Nordisk A/S Gentofte, 
Denmark. Dissolved in 0.1 ml 0.9% NaCI, it was given twice daily for 10 
consecutive days by s.c. injection (total daily dose 0.2 IU hGH/100 g body 
weight). This dose appeared to be physiological from dose-response studies by 
otbers (Jorgensen et al, 1987; Skottner et al., 1987). 
Animal preparation 
At tbe end of tbe treatment period animals were fasted for 18 hr and killed by 
exsanguination under pentobarbital anaestbesia. Aortal blood was collected, 
allowed to clot at 0°C and tbe serum was stored at -20°C. The liver was 
removed immediately and rinsed witb 0.9% NaCL Part of tbe liver was frozen 
in liquid nitrogen. The remainder was used for isolation of microsomes by 
differential centrifugation (Havinga et al., 1987), and microsomes were stored 
at -80°C. 
LDL isolation and labeling 
Human LDL was purified by ultracentrifugation (d 1.019-1.063 g/ml) from 
fresh plasma of healtby donors (Zechner et al., 1986). LDL was labeled with 
1251 as previously described (specific activity of 55 cpm/ng LDL 
protein)(McFarlane, 1956; Billheimer et aL, 1972). 
Analytical methods 
Determination of LDL receptor activity. 
LDL-R was quantified by a modified dot-blot assay (Maggi and Catapano, 
1987): Microsomes were suspended in 50 mM Tris-maleate pH 6.5, containing 
2 mM CaCl2, 1.5 mM PMSF, 0.1 mM leupeptine and 40 mM B-octyl-glucoside 
(buffer A)(leupeptine and B-octyl glucoside were obtained from Boehringer 
Mannheim, Germany). The suspension was sonicated twice for 5 sec and tbe 
undissolved material was pelleted by centrifugation for 4 min in an Eppendorf 
centrifuge at 10.000 x g. The B-octyl-glucoside soluble material was diluted to 
a final protein concentration of 0.2 mg/ml and 50 Ill of the membrane 
suspension was applied to nitrocellulose membranes using a manifold 
apparatus (Bio-Rad). Individual spots were washed witb 150 Ill of a buffer pH 
7.5, containing 10 mM Tris-HCI, 50 mM NaCl and 2 mM CaCI2 (buffer B). 
After blocking the unbound places for l h in buffer B containing 50 mg/ml 
BSA, the nitrocellulose filter was incubated for 16 h at 21 oc witb 16 Ill 
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labeled LDL (0.27 !lg/ml) in buffer B, washed at least 5 times with 150 111 
buffer B and dried for autoradiography (X-ray films were from Kodak, 
Badhoevedorp The Netherlands). Exposure was for 38 hours. Quantitative 
analysis was performed using a scanning densitometer (Videodensitometer 
model 620, Biorad). All measurement were done in triplicate. Specificity of 
binding was evaluated in the presence of a 20-fold excess of unlabeled LDL 
The effects of disodium EDTA (30 mM) and heparin ( 4 mg/ml) added to the 
incubation medium were evaluated. 
LDL receptor mRNA determination. 
RNA was prepared by the guanidine isothiocyanate/cesium chloride procedure 
(Chirgin et a!., 1979) from the liver of individual animals. Dotblot 
hybridizations of total cellular RNA were performed as described previously 
(Staels et a!., 1989). A 0.3-kb BamHI restriction fragment of the human LDL 
receptor clone pLDLR-3, corresponding to nucleotide position 1079-1450, 
was used for LDL-R mRNA determination (Staels et aL, 1990). A chicken 3 
actin probe was used as a control (Cleveland et a!., 1980), to normalize for 
events of differences in mRNA blotting. Filters were hybridized to 1.5 x 106 
cpm/ml of each probe as previously described (Staels et aL, 1989). They were 
washed in 500 ml 0.5 X sse (20 X sse= 3.0 M NaCl, 0.3 M Na3Citrate) and 
0.1 % SDS for 10 min at room temperature and twice for 30 min at 65°C and 
subsequently exposed to X-ray film (Hyperfilm-Bmax, Amersham, Arlington 
Heights, IL). Quantitative analysis was performed on autoradiograms of dot 
blot filters by scanning densitometry in the linear range of film sensitivity. 
Curves were plotted on a log/log scale relating the densitometric measurement 
to the amounts of mRNA in the corresponding dots. The relative amounts of 
mRNA were calculated in parallel parts of these curves. Part of this mRNA 
work was supported by a grant from Merck Sharp and Dohme to J. Auwerx. 
HMG-CoA reductase activity 
The activity of HMG-CoA reductase was determined in liver microsomes after 
dephosphorylation, as described by Balasubramanian et aL (1976). HMG-CoA 
reductase activity is expressed as pmol of [14C] mevalonate formed per mg 
microsomal protein/min. 
Statistical Methods 
Data are given as mean± standard deviation. For comparison between groups 
the Student's !-test and ANOV A were used. 
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RESULTS 
Effects of hypothyroidism and GH substitution on IGF-I levels and 
body weight gain. 
In hypothyroid animals plasma 1GF-I concentrations were decreased compared 
to controls, 1.99 ± 0.24 U/ml vs. 3.36 ± 0.52 U/ml (n=6, p<0.05) 
respectively. After treatment of hypothyroid rats with GH for 10 days the 
concentration of 1GF-1 became comparable to values in control rats: 3.74 ± 
0.48 U/ml vs 3.36 ± 0.52 U/ml (n=6). 
Body weights of the hypothyroid rats did not change during the last 10 days of 
the experiment (data not shown). However, hypothyroid rats substituted with 
GH gained 9 ± 3 g during the 10 days of GH-substitution (p<0.05 vs untreated 
hypothyroid rats), indicating that treatment with human GH induced a 
physiological growth response in rats. 
Effects of hypothyroidism and GH substitution on liver LDL-R 
expression and LDL-R mRNA. 
LDL-R was quantified by a ligand (1251-LDL) dotblot assay. The binding of 
1251-LDL to the blots exhibited the characteristics of binding of LDL to the 
LDL receptor. EDTA prevented, unlabeled LDL competed, and heparin 
completely reversed 1251-LDL binding to its receptor (Table 5.1). 
The effects of hypothyroidism on LDL-R was determined by comparing 
membrane preparations of rats treated or not with methimazole. In 
hypothyroid rats the expression of the LDL-R decreased significantly to 67 ± 
6 % of intact controls (Table 5.2). During GH treatment of hypothyroid rats 
the LDL-R expression was normalized. LDL-R mRNA fell in hypothyroid 
rats to 31 ± 6 % of the controls, while treatment with GH normalized LDL-R 
mRNA levels to those observed in intact controls (Figure 5. 1). 
Effects of hypothyroidism and GH substitution on hepatic 
microsomal HMG-CoA reductase activity. 
In hypothyroid rats the microsomal HMG-CoA reductase activity was greatly 
diminished to 36%, as compared to euthyroid rats (Table 5.2). Treatment with 
GH for 10 days increased the HMG-CoA reductase activity significantly. 
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Table 5.1: Effect of heparin, EDTA and excess unlabelled LDL on binding 
of 1251-LDL. LDL-R were incubated with labeled 1251-LDL for 1 
hr in the presence of heparin (4mg/ml), EDTA (30mM) or excess 
LDL (20 fold). Data are means of triplicate determinations. 
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Figure 5.1: Influence of GH on liver LDL receptor mRNA in hypothyroid rats. Liver 
mRNA levels for LDL receptor were measured by dot blot hybridization. 
Significant difference from control values and GH-treated hypothyroid animals 
is indicated by an asterisk (p<0.05). 
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Table 5.2: Effect of hypothyroidism with and without growth hormone (GH) 
substitution on low density lipoprotein receptor (LDL-R) 
expression and HMG~CoA reductase activity in liver microsomes. 
Data are presented as the mean ± SD for the number of rats in 
parentheses. Significant differences from control values and from 
the values of the GH treated animals, are indicated by an asterisk 
(p<O.OS). 
n LDL-R HMG-CoA reductase 
(relative absorbance units) (pmol/mg protein/min) 
Controls 6 100 ± 23 126±78 
Hypothyroids 6 67± 6* 45 ±23* 
Hypothyroids+GH 6 109±20 76±29 
DISCUSSION 
The depression of the rate of LDL-catabolism during hypothyroidism has been 
ascribed to the deficit of thyroid hormone (Valdemarsson, 1982; Gross et al., 
1987; Stae1s et al., 1990). However, in this study we showed, that in the 
absence of thyroid hormone, physiological levels of GH stimulate hepatic LDL-
R activity and LDL-R mRNA levels to normal values. This indicates that in 
the hypothyroid situation the deficit of GH influences the disturbances in lipid 
metabolism. The observed stimulation of LDL-R activity by GH (and/or IGF-
I), can either be direct or secondary to another effect on cholesterol 
homeostasis. In favor of a direct effect of GH on LDL-R, Veldhuis et al. 
showed, that IGF-I has a direct stimulating effect on the number of LDL 
receptors in swine granulosa cells (Veldhuis et al., 1987). However, the 
number of LDL receptors is inversely related to intracellular cholesterol 
concentration (Brown and Goldstein, 1986). To exclude an indirect 
stimulatory effect of GH on the LDL-R via a reduction of the intracellular 
cholesterol concentration, because of a decreased HMG-CoA reductase 
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activity, the microsomal activity of this enzyme was determined. In this study 
an increased HMG-CoA reductase activity was observed after treatment of 
hypothyroid rats with GH, thereby excluding a secondary effect of GH on 
LDL-R via a lowered cholesterol synthesis. 
The stimulation of both LDL-R and HMG-CoA reductase activity however, 
may be secondary to an increased use of cholesterol by the cells. For instance, 
in rapidly growing tissues, LDL-R are required to take up sufficient 
cholesterol to support new membrane synthesis (Goldstein et a!., 1983). In our 
experiments the body weight of the pubertal rats increased considerably 
during substitution with GH indicating that augmented use of cholesterol is 
likely. Alternatively, an augmented use of cholesterol can result from a 
stimulated bile acid synthesis. Stimulation of bile acid synthesis by GH has 
been shown in rats (Day et al., 1989) and in GH deficient children substituted 
with GH (Heube et a!., 1983). This leaves open the possibility of a secondary 
response of LDL-R to GH as a result of an augmented use. 
The physiological importance of the influence of GH on cholesterol 
metabolism is not yet clear. Recently a protective role of GH with regard to 
cardiovascular mortality was reported (Rosen and Bengtsson, 1990). In a 
retrospective study in patients with pituitary insufficiency substituted for all 
hormonal deficiencies but GH an increased cardiovascular mortality was 
shown as compared to controls, suggesting that, in addition to the well known 
effects of a lack of thyroid hormone (Becker, 1985) and estrogens (Gordon et 
al., 1978), a deficiency of GH may also increase the incidence of premature 
atherosclerosis. 
In summary, a stimulating effect of GH on hepatic cholesterol metabolism in 
hypothyroid rats is shown in this study. The decrease in LDL-cholesterol 
during GH treatment (Hoogerbrugge-v.d.Linden eta!, 1990; Chapter 3), may 
be caused by an activation of the LDL receptor by GH and/or IGF-I. 
REFERENCES 
1. Balasubramanian, S., Goldstein, J.L., Faust. J.R. & Brown, M.S. 1976. Evidence for 
regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and cholesterol 
synthesis in nonhepatic tissue of rat. Proceedings of the National Academy of Science. 
USA 73, 2564-2568. 
78 Lipid metabolism in hypothyroidism 
2. Becker, C. 1985. Hypothyroidism and atherosclerotic heart disease: pathogenesis, 
medical management and the role of coronary artery bypass surgery. Endocrine 
Reviews 6, 432-440. 
3. Billheimer, D.W., Eisenberg, S. & Levy, R. 1972. The metabolism of very low 
density lipoprotein proteins. Biochemical Biophysical Acta 260,212-221. 
4. Brown, M.S. & Goldstein, J.L. 1986. A receptor-mediated pathway for cholesterol 
homeostasis. Science 232, 34-47. 
5. Byers, S.O .. Friedman, M. & Rosenman, R.H. 1970. Prevention of 
hypercholestero1aemia in thyroidectomized rats by growth hormone. Nature 228, 464-
465. 
6. Chait, A., Bierman, E.L. & Albers, J.J. 1979. Regulatory role of triiodothyronine in 
the degradation of low density lipoprotein by cultured human skin fibroblasts. Journal 
of Clinical Endocrinology and Metabolism 48, 887-889. 
7. Chirgin, J.M .. Przybyla, A.E .. MacDonald, R.J. & Rutter, W.J. 1979. Isolation of 
biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 
18, 5294-5297. 
8. Cleveland, D.W .. Lopata. M.A., MacDonald, R.J., Cowan, M.J.. Rutter, W.J. & 
Kirschner, M.W. 1980. Number and evolutionary conservation of alpha- and B-tubulin 
and cytoplasmic B-and gamma-actin genes using specific cloned eDNA probes Cell 20. 
958- 962. 
9. Day, R., Gebhart, H.L., Schwartz. H.L .. Sttait. K.A., Duane, W.C .. Stone, B.G. & 
Oppenheimer, J.H. 1989. Time course of hepatic HMG-CoA reductase activity and 
mRNA. biliary lipid secretion, and hepatic cholesterol content in methimazole-treated 
hypothyroid and hypophysectomized rats after triiodothyronine administration: possible 
linkage of cholesterol synthesis to biliary secretion. Endocrinology 125, 459-468. 
10. Dory. L. & Roheim. P.S. 1981. Rat plasma lipoproteins and apolipoproteins in 
experimental hypothyroidism. Journal of Lipid Research 22, 287-296. 
11. Friedman, M .. Byers, S.O., Rosenman, R.H., Li. C.H. & Neuman, R. 1974. Effect 
of subacute administration of human growth hormone on various serum lipid and 
hormone levels in hypercholesterolemic and normocholesterolemic subjects. 
Metabolism 23, 905-912. 
12. Goldstein, J.L., Kita, T. & Brown, M.S. 1983. Defective lipoprotein receptors and 
atherosclerosis. New England Journal of Medicine 309, 288-296. 
13. Gordon, T., Kannel, W.B .. Hjortland ,M.C. & McNamara. P.M. 1978. Menopause 
and coronary heart disease: The Framingham Study. Annals of Internal Medicine 89, 
157-161. 
14. Gross, G .. Sykes, M., Arellano, R., Fong, B. & Angel, A. 1987. HDL clearance and 
receptor-mediated catabolism of LDL are reduced in hypothyroid rats. Atherosclerosis 
66, 269-275. 
15. Havinga. J.R., Lohse. P. & Beisiegel. U. 1987. lmmunoblotting and ligand blotting of 
the low-density lipoprotein receptor of human liver, HepG2 cells and HeLa cells. 
FEBS Lett 216, 275-280. 
16. Heube, J.E., Burstein, S., Sperling, M.A., Gregg, D .. Subbai, M.T.R. & Matthews, 
D.E. 1983. The role of human growth hormone in the regulation of cholesterol and bile 
acid metabolism. Journal of Clinical Endocrinology and Metabolism 57, 885-891. 
Chapter 5 79 
17. Hoogerbrugge-v.d.Linden. N .. Jansen. H.. Hulsmann. W.C. & Birkenhager. J.C. 
1989. Relationship between insulin-like growth factor-! and low-density lipoprotein 
cholesterol levels in priroary hypothyroidism in women. Journal of Endocrinology 123. 
341-345. 
18. Hoogerbrugge-v.d.Linden. N .• Jansen. H .• Wouters. N.M.H. & Birkenhager. J.C. 
1990. Growth hormone and thyroxine affect lipoprotein metabolism in hypothyroid and 
hypophysectomized rats. Journal of Endocrinology 125. 403-407. 
19. Jorgensen. K.D. 1987. Comparison of the pharmacological properries of pituitary and 
biosynthetic human growth hormone. Acta Endocrinologica 114. 24-131. 
20. Katakami. H .• Downs. T.R. & Frohman. L. 1986. Decreased hypothalamic growth 
hormone-releasing hormone content and pituitary responsiveness in hypothyroidism. 
Journal of Clinical Investigation 77. 11704-11711. 
21. Maggi. F.M. & Catapano. A.L. 1987. A dot-blot assay for the low density lipoprotein 
receptor. Journal of Lipid Research 28. 108-112. 
22. Martin. D .• Epelbaum, J., Bluet-Pajot, M., Prelot, M., Kordon, C. & Durand, D. 
1985. Thyroidectomy abolishes pulsatile growth hormone secretion without 
hypothalamic somatomedin. Neuroendocrinology 41,476-481. 
23. McFarlane, A.S. 1956. Labelling of plasma proteins with radioactive iodine. 
Biochemical Journal62, 135-143. 
24. Nikkilii, E.A. & Pelkonen, R. 1975. Serum lipids in acromegaly. Metabolism 24, 829-
838. 
25. Rosen, T. & BengtSson, B. 1990. Premature mortality due to cardiovascular disease in 
hypopiruitarism. Lancet 336, 285-288. 
26. Scarabottola, L., Trezzi, E., Roma, P. & Catapano, A.L. 1986 Experimental 
hypothyroidism modulates the expression of the LDL receptor by the liver. 
Atherosclerosis 59, 329-333. 
27. Skottner, A., Clark, R.G .. Robinson, !.C.A.F. & Fryk!und, L. 1987. Recombinant 
human insulin-like growth factor : testing the somatomedin hypothesis in 
hypophysectomized rats. Journal of Endocrinology !12, 123-132. 
28. Staels, B., Auwerx, J., Chan, L., van To!, A., Rosseneu, M. & Verhoeven, G. 1989. 
Influence of development. oestrogens and food intake on apolipoprotein A-I, A-II and 
E mRNA in the rat liver and intestine. Journal of Lipid Research 30, 1137-1141. 
29. Staels, B., van To!, A., Chan, L., Will, H., Verhoeven, G. & Auwerx, J. 1990. 
Alteration in thyroid status modulate Apolipoprotein, hepatic triglyceride-lipase and 
LDL receptor in rats. Endocrinology 127, 1144-1152. 
30. Sykes. M., Cnoop-Koopmans, W.M .. Julien, P. & Angel, A. 1981. The effects of 
hypothyroidism, age and nutrition in the rat. Metabolism 30, 733-738. 
31. Thompson, G.R., Soutar, A.K., Spengel, F.A., Jadhav, A., Gavigan, S.J.P. & 
Myant, N.B. 1981. Defects of receptor-mediated low density lipoprotein catabolism in 
homozygous familial hypercholesterolemia and hypothyroidism in vivo. Proceedings of 
the National Academy of Science, USA 78,2591-2595. 
32. Valdemarsson, S. 1982. Reversal of decreased hepatic lipase and lipoprotein lipase 
activities after treatment of hypothyroidism. European Journal of Clinical Investigation 
12. 423-428. 
80 Lipid metabolism in hypothyroidism 
33. Veldhuis, J.D., Nestler, J.E. & Strauss, J.F. 1987. The insulin-like growth factor, 
somatomedin-c, modulates low density lipoprotein metabolism by swine granulosa 
cells. Endocrinology 121, 340-346. 
34. Walton, K.W., Scott, P.J., Dykes, P.W. & Davies, J.W.L. 1965. The significance of 
alterations in serum lipids in thyroid dysfunction. Clinical Science 29, 217-238. 
35. Wood, D.F., Franklyn, J.A., Ramsden, D.B. & Shepperd, M.C. 1987. The effect of 
thyroid hormones on growth hormone gene expression in vivo in rats. Journal of 
Endocrinology 112. 459-463. 
36. Zechner, R., Meser, R. & Kostner, G.M. 1986. Isolation of pure LpB from human 
serum. Journal of Lipid Research 27, 681-686. 
Chapter 5 81 
82 Lipid metabolism in hypothyroidism 
Chapter 6. 
INSULIN-LIKE GROWTH FACTOR-I STIMULATES THE LDL-
RECEPTOR ACTIVITY IN HEPG2 CELLS. 
N. Hoogerbrugge. H. Jansen. N.M.H. Wouters and J.C. Birkenhager. 
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ABSTRACT 
In man as well as in the rat hypothyroidism is accompanied by an increased 
LDL-cholesterollevel, probably due to a decrease in LDL-receptor activity. 
Besides thyroid hormone also growth hormone (GH) is deficient in this state. 
The possible role of T3, T4, GH and insulin-like growth factor I (IGF-l) in the 
receptor mediated catabolism of LDL was studied in HepG2 cells. 
HepG2 cells were incubated with fetal calf serum from hypo- and euthyroid 
animals. Both binding and internalization of 1251-LDL by HepG2 cells were 
approximately 50% (p<0.05) lower after incubation with hypothyroid FCS, as 
compared to using euthyroid FCS. 
In serum free conditions "physiologic" concentrations T3, T4 and GH, were 
without effect on either binding or internalization of 1251-LDL by HepG2 
cells. Insulin-like growth factor I (IGF-I) stimulated both binding and 
internalization of 1251-LDL by HepG2 cells cultured in serum free condition 
by 50% (p<O.Ol). 
We conclude that IGF-I may play a regulatory role in cellular cholesterol 
metabolism by direct effect on LDL uptake by the liver. 
INTRODUCTION 
Elevation of serum cholesterol concentration is characteristically seen in 
untreated hypothyroidism in man (Peters and Man, 1950; Mishkel and 
Crowther, 1977; Abrams and Grundy, 1981; Lithell et aL, 1981; Muls et aL, 
1984 ). The catabolic rate of low-density lipoprotein (LDL), the major 
transport form of serum cholesterol, is slowed in hypothyroidism (Walton et 
aL, 1965). This is mainly the result of a decreased expression of LDL 
receptors on the liver membranes (Thompson et aL, 1981; Scarabottolo et aL, 
1986). 
Generally, the effects of hypothyroidism on LDL-cholesterolholesterol 
catabolism are considered to be due to lowered thyroid hormone levels. 
However, during hypothyroidism both thyroid hormone and growth hormone 
(GH) are deficient (Iwatsubes et aL, 1967; Katakami et aL, 1986; Chernausek 
and Turner, 1989). In hypothyroid rats we showed that treatment with GH or 
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thyroxine (T4) both enhance LDL metabolism (Hoogerbrugge-v.d.Linden et 
aL, 1990; Chapter 3). In patients with untreated and treated hypothyroidism, 
we found that LDL-cholesterol was related to IGF-I levels rather than to those 
of free T4 (Hoogerbrugge-v.d.Linden etaL, 1989; Chapter 2). 
We report here the effects of triiodothyronine (T3), T 4, GH and IGF-I on 
LDL binding to its receptor and on LDL internalization in a human hepatoma 
cell line HepG2. 
MATERIALS AND METHODS 
Preparation of LDL. 
Human plasma was prepared from pooled fresh blood obtained from healthy 
donors. LDL was isolated from plasma by sequential ultracentrifugation using 
the method of Zechner et aL (1986). Briefly, the lipoproteins of d 1.020-1.063 
g/ml were prepared by ultracentrifugation in a fixed angle rotor, washed and 
concentrated by density gradient ultracentrifugation. This LDL preparation 
was immediately used for iodination. Radioiodination was performed 
according to the method of McFarlane (1956), as modified by Billheimer et al. 
(1972). After iodination LDL was dialyzed for 24 hr against Williams E 
supplemented with 20 mM hepes buffer (pH 7.4 ), penicillin and streptomycin, 
stabilized by the addition of I% human serum albumin (HSA) and stored at 4 o 
C. For binding experiments, 1251-LDL was diluted with unlabeled LDL to 
give .a specific radioactivity of 35 - 40 cpm/ng LDL protein. The iodinated 
LDL was used within 2 weeks. The free iodine fraction of the 125!-labelled 
LDL samples was less than I %. 
When not labelled with 125Jodine, LDL was immediately stabilized by the 
addition of 1% HSA and extensively dialyzed against Williams E supplemented 
with hepes (pH 7.4 ), penicillin and streptomycin. 
Culturing of HepG2 cells 
The HepG2 cell line was maintained in Williams E (Flows laboratories, Great 
Britain), supplemented with 10 % heat inactivated fetal calf serum (FCS), 
penicillin (100 U/ml) and streptomycin (I !J.g/ml) at 37 °C in a humidified 95 
% air - 5% C02 atmosphere. 11Je medium was renewed twice a week. For 
binding experiments the cells were seeded in 6-well plates (Costar. 
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Cambridge, MA). All experiments were initiated 6 days later after cells had 
been incubated for 48 hr in the presence of medium containing either I 0% 
FCS, 10% hypothyroid FCS or I% HSA. Hormones were added to the HSA 
containing media for the last 48 hr of incubation as indicated. 
LDL Binding experiments. 
The cells were washed shortly before the experiment, to remove serum, and 
incubated three times with Williams E supplemented with 1% HSA, during a 
period of 30 min at 37 °C. The experiment was started by replacing medium 
by 1 ml Williams E containing 20 mM Hepes pH 7.4, 1 % HSA and various 
amounts of 1251-labelled LDL. Non specific binding was determined by the 
addition of a 20 fold excess of cold LDL. Dishes without cells were used as 
controls. After 3 hr of incubation at 37 °C the medium was removed, each cell 
plate was cooled to 0°C and washed rapidly 3 times with 3 ml of ice cold 
solution containing 0.15 M NaCl, 50 mM Tris-chloride (pH 7.4) and 2 mg/ml 
of bovine albumin. The mono layers were then incubated twice for 10 min at 
4°C with 3 ml of the above NaCl-Tris-albumin solution, followed by one rapid 
wash with 3 m1 of solution containing 0.15 M NaCl and 50 mM Tris-Chloride 
(pH 7.4). After washing, the cells were incubated with heparin (10 mg/ml) 
containing NaCl-Tris buffer for l hr at 0 °C (Goldstein et al., 1976). The 
radioactivity released into the heparin buffer reflects the amount of 125!-LDL 
bound to the plasma membrane. Cells were dissolved in 1 M NaOH. The 
radioactivity in the cell lysate represents the total amount of 1251-labelled LDL 
that became internalized. A portion of the cell lysate was used for protein 
determination by the method of Lowry with BSA as standard. All experiments 
were done in duplicate. 
Materials. 
3,3',5-Triiodo-L-thyronine (sodium salt) was a product from Sigma Chemical 
Company (London, Great Britain). hGH (Norditropin) was a generous gift 
from Novo-Nordisk. Recombinant hiGF-I analog was obtained from 
Amersham (Buckinghamshire, Great Britain). 
Statistical methods 
All incubations were performed in triplicate and results are reported as mean 
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± SD. Differences were considered to be statistically significant when p<0.05 
using Student's t-test. 
RESULTS 
Effects of hypothyroid FCS on LDL receptor expression of HepG2 
cells. 
In Figure 6.1, binding and internalization of 1251-labelled LDL by cultures of 
HepG2 cells incubated for 48 hr with medium supplemented with 10 % FCS 
or 10 % hypothyroid FCS are shown. The expression of the LDL-receptor, 
measured by binding and internalization of 125!-LDL is approximately 50 % 
(p < 0.01) lower after incubation with hypothyroid FCS as compared to FCS 
of euthyroid animals. 
Effect of T3, T4, GH and IGF-I on LDL receptor expression by 
HepG2 cells. 
HepG2 cells were incubated in 1 % HSA with either T3 (0.1, 1, 10 and 100 
nM), T4 (0.1, 1, 10 and 100 nM), GH (0.1, 1, 10 and 100 Jlg/ml) or IGF-I 
(0.1, 1, 5 and 10 nM). The binding and internalization of 125!-LDL (10 and 
50 Jlg/rnl) were not affected by incubation with different doses of T3, T 4 or 
GH (Data not shown). On the other hand IGF-I in a concentration of 10 nM 
increased both binding and internalization of 1251-LDL (10 and 50 Jlg/rnl) by 
approximately 50 %, as is shown in Table 6.1 and Figure 6.2. Lower levels of 
IGF-I (5 nM or less) did not affect the expression of the LDL-receptor. Table 
6.1 shows the data of binding and internalization of 125LDL, for the maximal 
hormone concentration used; that is 100 nM T3, 100 Jlg/ml (=0.29 U/ml) GH 
and 10 nM IGF-I. 
DISCUSSION 
We have presented evidence that the LDL-receptor of HepG2 cells is sensitive 
to stimulation by IGF-I at high concentrations. However the more 
"physiological" concentration, 1 nM did not stimulate LDL-receptor 
expression. For some years it is known that HepG2 cells have receptors for 
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Figure 6.1: Effects of incubations of HepG2 cells for 48 hr with 10 % fetal calf serum 
(FCS) (triangles, drawn line) or 10% hypothyroid FCS (dots, broken line) on 
the receptor-mediated binding and uptake of 5 - 80 ~g/ml 125!-LDL. The 
inhibition by hypothyroid FCS was statistically significant for the LDL 
concentrations indicated by an asterisk (p<0.05). Symbols represent means ± 
SD of three wells for each condition. 
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Figure 6.2: Effects of incubations of HepG2 cells for 48 hr in serum free medium 
supplemented with I% HSA and insulin like growth factor-! (!GF-l) on the 
receptor mediated binding and uptake of 10 (triangles. dottewd line) and 50 
J.lg/ml (dots. drawn line) 125!-LDL. The stimulation by IGF-l was statistically 
significant for the IGF-I concentrations indicated by an asterisk (p<0.05). 
Symbols represent means± SD of two separate experiments. 
90 Lipid metabolism in hypothyroidism 
Table 6.1: Effects of incubation of HepG2 cells triiodothyronine (T 3) or 
growth Hormone (GH) on the receptor~mediated binding and 
uptake of 50 ~g/ml 125!-LDL 
Relative Relative 
binding to internalization by 
LDL-receptor LDL-receptor 
Addition % % 
none 100 100 
T3 (100 nM) 105 ± 15 90± 4 
GH (100 ~g/ml) 110 ± 13 105 ± 23 
IGF-l (10 nM) 156 ± 7 * 150±15* 
Cells were cultured for 48 hr in the presence of 1% HSA with the indicated 
concentrations of hormones. The specific binding and internalization was measured at 
37 °C for 3 hr and expressed per mg cell protein. Results are mean ± SD for 2 
independent experiments and are expressed relative to the binding or internalization in 
the absence of added hormones. The hormonal treatment did not affect the recovery of 
cell protein. 
*Significantly increased as compared to cells without hormonal addition p<O.Ol. 
IGF-I (Verspohl eta!., 1988). Veldhuis (Ve1dhuis et al., 1987) showed that 
IGF-I enhanced the LDL-receptor activity in swine granulosa cells. So far it 
was not known whether IGF-I also affects LDL metabolism in parenchymal 
liver cells, the most important cell in LDL metabolism. A stimulatory effect 
of IGF-I on the LDL-receptor of liver like cells, as shown in this study, 
supports the hypothesis that GH-activity, has a function in the physiologic 
regulation of LDL metabolism and that a deficiency of GH activity, either 
primarily or for instance during hypothyroidism, will add to the impairment 
of LDL catabolism (Hoogerbrugge eta!, 1990; Chapter 3). 
IGF-I is thought to partly mediate the growth stimulating effects of GH 
(Daughaday et a!., 1972). It is produced in many tissues, notably the liver 
(Phillips and Vassilopoulou-Sellin, !980). In liver cells GH can directly induce 
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IGF-I mRNA (Norstedt and Moller, 1987), while in fibroblasts it was shown 
that GH stimulates IGF-I production in a dose dependent manner (Clemmons 
et aL, 1980). In our study GH, in contrast to IGF-I, did not enhance the LDL-
receptor activity. It was shown that in serum free medium the HepG2 cell line 
does not secrete significant quantities of IGF-I (Moses et aL, 1983). 
Therefore, the amount of GH given to the HepG2 cells during incubation 
probably did not induce sufficient amounts of IGF-I to activate the 
LD L-receptor. 
T3 used in a concentration up to 100 nM, and also T4 in a dose up to 100 nM, 
were not able to stimulate LDL-receptor binding and internalization. In fibro-
blasts a concentration of I 0 nM T 3 stimulated both binding and internalization 
(Chait et aL, 1979). Salter et aL (1988) showed that a dose of 10 nM T3 
induced a 30 % increase in LDL-receptor binding, in rat hepatocytes. The 
concentration T3 that was used, was based on the physiological situation. 
Possibly higher concentrations of thyroid hormone could show an effect on 
the LDL-receptor in HepG2 cells. A stimulatory effect of 5000 nM Thyroxine 
(T 4) on the testosterone-estradiol-binding globulin production of HepG2 cells 
has been shown (Rosner et aL, 1984 ). As the T 3 and T 4 concentration in FCS 
are 0.71 and 16 nM respectively, the use of FCS for cell culturing can not be 
the explanation for the difference in LDL-receptor expression between cells 
incubated with hypothyroid or normal FCS. Hypothyroid FCS differs from 
FCS in more respects than just the concentration of thyroid hormones e.g. 
lipoprotein levels, creatine phosphokinase activity and IGF-I concentration. 
Which factors are responsible for the decreased LDL-receptor expression 
after incubation with hypothyroid FCS we do not know, but a distinct role for 
IGF-I in LDL metabolism has been demonstrated. 
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GROWTH HORMONE NORMALIZES HEPATIC LIPASE mRNA 
LEVELS AND ACTIVITY IN HYPOTHYROID RAT LIVER. 
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ABSTRACT 
The effect of growth hormone (GH) administration on hepatic lipase (HL) 
activity and mRNA levels were studied in pair-fed hypothyroid rats. In the 
hypothyroid state liver HL mRNA levels as well as liver- and postheparin 
plasma-HL activities were decreased. In hypothyroid rats GH normalized HL 
mRNA levels and HL-activity in postheparin plasma. GH also increased the 
activity of HL in the liver, which remained lower than in controls. These data 
indicate that at least part of the lowering of HL during hypothyroidism is due 
to the concomitant GH deficiency and that GH, rather than thyroid hormone, 
may regulate HL mRNA levels. 
INTRODUCTION 
Hepatic lipase (HL) exerts a regulatory influence on the concentration and 
characteristics of lipoproteins in plasma (1,2). The activity of HL is affected 
by several hormones; e.g. estrogens, corticosteroids and insulin (3,4). During 
hypothyroidism one of the most consistent changes in lipid variables is a 
decreased HL-activity (5,6). In hypothyroids not only thyroid hormone is 
deficient, but also the synthesis, secretion and activity of growth hormone 
(GH) are decreased (7 ,8). Recently we reported that in hypothyroid rats 
treatment with GH increased HL-activity ( 6). Therefore, we studied the effects 
of GH replacement on mRNA levels in liver tissue and on HL-activity in 
plasma of hypothyroid rats. Since hypothyroids have a decreased basal 
metabolism and eat less than controls, while a decreased food intake is known 
to lower HL-activity (4,9), the studies were carried out with pair-fed animals. 
MATERIALS AND METHODS 
Animals 
Male Wistar rats aged 6-7 weeks, weighing 140 ± 6 g were used. 
Animal treatment 
Rats were fed a vegetarian laboratory chow and had free access to drinking 
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water. 
Paired feeding Food intake of all animals was restricted to the amount ingested 
by the animals with lowest food intake. The animals were housed together. but 
fed separately for 2 hours a day. Hypothyroid rats had lowest food intake. The 
amount eaten by a hypothyroid rat was weighted, and the same amount was 
given to a control and a GH treated rat. 
Hypothyroidism was induced by the addition of 0.05 % 2-mercapto-1-methyl-
imidazole (Janssen Chimica, 2340 Beerse Belgium) to the drinking water. 
When after 14 days T 4 was less than 1 nmol/l the administration of GH was 
started. 
GH (Norditropin, Novo-Nordisk, Denmark) was administered s.c. for 10 days 
twice daily, in a daily dose of 0.2 IU/100 g dissolved in 0.1 ml 0.9 % NaCl. 
This dose appeared to be physiological from dose response studies by others 
(ll), and of maximal duration (12). Hypothyroid and control animals were 
injected twice daily with 0.05 m1 0.9 % NaCl. 
Animal preparation 
After overnight fast animals were anaesthetized with pentobarbital. Post 
heparin plasma was obtained from the aorta 6 minutes after i.v. administration 
of 50 IU heparin (Tromboliquine, Organon Oss, The Netherlands). The 
plasma was kept on ice and immediately used for the determination of 
HL-activity. Other rats were killed by decapitation, the livers were removed. 
A part of this liver was kept on ice for determination of HL-activity. An other 
part of the liver was frozen in liquid nitrogen and stored at -80°C until mRNA 
analysis. 
Analytical methods 
The IGF-I concentration in plasma was determined by radioimmunoassay, 
using a testkit (Nichols institute diagnostics, San Juan Capistrano, USA). 
Determination of HL 
HL-activity was determined by a triglyceridase assay pH 8.5 in 0.6 M NaCl 
using a gum acacia-stabilized glycerol [9,10(n)-3H]trioleyl emulsion as 
substrate (2). Determination of HL-activity in plasma and liver samples were 
each done in one assay. Both assays were carried out in duplicate. The 
coefficient of variation of the assay was 10 %. In plasma, HL-activity was 
measured as the anti-HL inhibitable salt-resistant lipase using a polyclonal goat 
anti- HL. 
HL mRNA determination. 
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HL mRNA determination was done, exactly as described (9). 
Statistics 
Data are given as mean ± standard deviation. Multiway analysis of variance 
was used to evaluate the results. 
RESULTS 
GH activity. 
In hypothyroid rats GH activity, reflected in the circulating IGF-I 
concentration, was decreased as compared to controls 1.50 ± 0.12 U/ml 
(n=l2) and 3.30 ± 0.18 U/ml (n=l2, p<0.01), respectively. During treatment 
with GH of hypothyroid rats, the plasma IGF-I concentration was increased as 
compared to hypothyroid rats to 2.43 ± 0.24 U/ml (n=13, p<0.05). 
In control rats pair-feeding led to a less pronounced body weight gain (BWG) 
over the last 7 days of the experiments as compared to ad libitum fed rats 9 ± 
6 g (n=4) and 33 ± 6 g (n=4, p<0.05), respectively. Pair-feeding did not affect 
BWG of hypothyroid rats or GH treated hypothyroid rats; while body weight 
of hypothyroid rats did not change, GH treated hypothyroid rats gained 9 ± 3 
g over the last 7 days. 
Hepatic lipase activity. 
Food restriction decreased HL-activity in liver homogenates of controls from 
1385 ± 193 mU/g (n=4) to 810 ± 44 mU/g (n=4; p<0.05). Under pair-fed 
conditions the activity of HL in hypothyroid rats was decreased as compared 
to controls (p<0.05, Table 7.1), while GH replacement stimulated the 
HL-activity in the liver homogenates with 21 % (p<0.05, Table 7.1). 
HL-activity in the post-heparin plasma was also decreased in the hypothyroid 
rats, but to a lesser degree than in the homogenates (-15%). Upon GH 
administration the activity of HL in post-heparin plasma returned to control 
values (Table 7.1). 
Hepatic lipase mRNA. 
To study whether the effects of GH and HL-activity could be in the synthesis 
of the enzyme, the level of mRNA for HL was. determined in liver 
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homogenates of pair-fed animals. Livers from hypothyroid rats contained 
!essHL mRNA than euthyroid controls ( -27%. p<0.05). Treatment with GH of 
hypothyroid rats increased HL rnRNA to control values (Table 7.1). 
Table 7.1: Effect of hypothyroidism with or without growth hormone (GH) replacement. 
on the level of hepatic lipase (HL) rnRNA and activity in homogenized liver 
tissue and on HL-activity in plasma obtained 6 min after intravenous injection 
with heparin 50 IU. Results are means ± sd. for a group of four rats. 
Significant differences from control values are indicated by an asterisk 
(p<0.05). Values of rnRNA were measured of individual animals by a dotblot 
hybridization technique. autoradiograms were scanned. Values are expressed in 
arbitrary units (U) taking the mean value of control groups as 100 U. 
HL-activity mRNA HL-activity 
liver liver plasma 
(mU/g) (U) (mU/ml.) 
Control 810 ± 44 100± 8 558 ± 27 
Hypothyroid 479±59* 73±20* 474±23* 
Hypothyroid+GH 578±54 104 ± 12 544± 14 
CONCLUSION 
The present study confirms earlier studies showing that during 
hypothyroidism HL rnRNA levels and activity in the liver are decreased. 
During hypothyroidism GH activity, measured by body weight gain and 
plasma IGF-I concentration are decreased. GH administration restores IGF-I 
levels but not thyroid hormone concentations. In this situation, 
hypothyroidism with increased IGF-I concentrations, HL mRNA was found to 
be normalized. This suggests that the well-known lowering of HL during 
hypothyroidism is at least partly due to the accompanying GH deficiency 
rather than to the low thyroidhormone concentration it self. Earlier we 
showed that in hypophysectomized (GH deficient) rats, thyroid hormone did 
not affect HL-activity. However, after GH substitution thyroid hormone 
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induced an increase in HL-activity (6). Secretion of HL by rat liver cells in 
vitro, in the absence of GH, was found not to be affected by T3 (12). We 
conclude that GH, presumably via IGF-I, regulates HL mRNA levels. This 
effect could be exerted on transcription or on the stability of the mRNA. 
Thyroid hormone alone does not regulate HL expression at the mRNA level, 
but may act (post)transcriptionally or and, presumably, only in the presence of 
GH (IGF-I). 
An apparent discrepancy was found between postheparin plasma HL-activity, 
which was normalized by GH, and HL-activity in the liver, which increased 
but remained lowered during GH administration. Under the present conditions 
the plasma HL-activity may not represent the hepatic HL content as we found 
that during hypothyroidism HL-activity after heparin injection disappears less 
rapidly from the plasma, suggesting a delayed clearance rate, leading to 
erroneous plasma values. The HL-activity in the liver during T3 and GH 
substitution seems to reflect the physiologically activity, as we found in a 
previous study that under these conditions, plasma HDL-cholesterol 
concentrations varied oppositely to the HL-activity. 
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GROWTH HORMONE DECREASES PLASMA CHOLESTEROL 
INDEPENDENT FROM THYROID HORMONE ACTIVITY. 
N. Hoogerbrugge, A. Binnerts, H. Jansen, J.C. Birkenhager and 
S.W.J. Lamberts. 
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ABSTRACT 
Growth hormone (GH) replacement leads to a decrease in serum cholesterol 
concentration and an increase in serum T 3 in GH-deficient adults. While both 
GH and thyroid hormone can decrease serum cholesterol concentration in man 
and rat, there is no consensus whether the cholesterol decreasing effect of GH 
is mediated by an increase in T3. We examined the effect of GH replacement 
therapy on plasma cholesterol levels and thyroid hormone concentrations in 8 
GH-deficient human adults and in GH-deficient rats, as well as control rats. 
In humans GH treatment caused a decrease in total serum cholesterol from 
5.3 ± 0.9 mM at baseline, to 4.6 ± 0.6 mM after one month of substitution 
(p<0.05). During this period serum T3 increased from 1.44 ± 0.36 to 1.95 ± 
0.42 nM (p<0.05) together with a decrease in serum T4 concentrations. 
In hypophysectomized rats (n=l6) treated with GH plasma cholesterol was 
decreased when compared to their controls (3.0 ± 0.0 mM and 4.0 ± 0.4 mM 
(p<0.05), respectively). In rats made hypothyroid by methimazole treatment 
similar changes were observed. T 3· nor T 4 concentrations changed after 
replacement treatment with GH, neither in hypophysectomized (n=8), nor in 
hypothyroid rats (n=8). 
It is still uncertain whether the cholesterol decreasing effect of GH in humans 
is mediated by an increase in circulating T3, by of a stimulated peripheral 
deiodination ofT 4 . Our data in rats are consistent with a GH-induced decrease 
in plasma cholesterol independent from circulating thyroid hormone 
concentration. 
INTRODUCTION 
Growth hormone (GH) administered in high doses to hypercholesterolemic 
adults acutely lowers the plasma cholesterol concentration (Friedman et aL, 
197 4 ). This cholesterol decreasing effect of GH is confirmed in several other 
studies. For instance, in patients with acromegaly a lowered plasma cholesterol 
concentration is found (NikkiHi and Pelkonen, 1975), and in adults with GH-
deficiency increased cholesterol levels have been described (Merimee et aL, 
1972; Merimee, 1980). Recently in a long -term ( 6 month) placebo controlled 
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GH-substitution study of GH-deficient adults it was shown that GH lowers 
cholesterol levels (Salomon et a!., 1989). Also in GH-deficient 
(hypophysectomized) rats the administration of GH lowers plasma cholesterol 
(Hoogerbrugge-v.d.Linden et al., 1990; Chapter 3). Although a cholesterol 
decreasing effect of GH is generally accepted, the mechanism of its effect(s) 
on cholesterol metabolism has not been extensively studied. 
Thyroid hormone has a well known lowering effect on the plasma cholesterol 
concentration in humans and animals (Abrams and Grundy, 1981; Dory and 
Roheim, 1981; Muls eta!.. 1984). Lately it was shown that GH treatment of 
GH-deficient adults stimulates the peripheral conversion of T4 to T3 (Grunfeld 
et al., 1988; Jorgensen et al., 1989). In the present study the effect of GH 
substitution on plasma lipid and thyroid hormone concentrations in GH-
deficient patients are reported. In addition to this, data are provided on the 
effects of GH substitution on these parameters in GH-deficient 
(hypophysectomized or hypothyroid) and control rats. 
PATIENTS, ANIMALS AND METHODS 
Patients 
Eight adults (3 men and 5 women, 25 to 46 years of age) with GH deficiency 
for at least l 0 years (congenital or after surgery for craniopharyngioma) were 
studied. If present, other hormonal insufficiencies had been adequately 
substituted for at least one year before the study. The presence of GH 
deficiency was confirmed by the combination of a plasma IGF-I level of 0.3 
U/ml or less (normal 0.34-1.90 U/ml in men and 0.45-2.20 U/ml in women). 
and a peak GH level of less than 10 mUll after lJJ.g/kg GHRH i.v. None of the 
patients suffered from renal or liver disease, diabetes mellitus or had a history 
of malignancy. Written informed consent was obtained from each patient 
before the start of the study. which was approved by the Medical Ethics 
Committee of the University Hospital Dijkzigt. 
Patient treatment procedures 
All individuals were studied for a period of 9 months. during which other 
hormonal substitution was not changed. The patients were asked not to alter 
their diet and level of physical activity. They received GH during the first 6 
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months. only. GH (Humatrope; Eli Lilly and Co. Indianapolis. USA) was 
injected s.c. by the patients themselves at bedtime, in a dose of 25 !lg/kg/day, 
with a maximum of 1.48 mg ( 4 IU). At the start of the study and at 1 ,3 and 6 
months after the start as well as 3 months after the end of GH administration 
blood samples were taken after an overnight fast. Lipids were determined as 
well as lipoprotein lipase (LPL) and hepatic lipase (HL) activity in plasma 
obtained 20 min after the injection of 50 IU heparin/kg BW. 
Animals 
Male pubertal Wistar rats, 6-7 weeks of age and weighing 185 ± 10 (SD) g. 
were used. They were housed at 21 °C on a 12 h cycle of light/darkness (lights 
on at 07.30 h). Vegetarian chow and drinking water were available ad libitum. 
Animal treatment procedures 
Hypothyroidism 
Hypothyroidism was induced by the addition of 0.05 % (w/v) 2-mercapto-1-
methyl-imidazole (Janssen Chimica. 2340 Beerse, Belgium) to the drinking 
water and given during the entire study. 
Hypophysectomy 
Hypophysectomy was carried out by the parapharyngeal approach (Thongren. 
Hansson, Menander-Selman and Stenstrom, 1973). Rats were given a 
precautionary s.c. injection of 50.000 IU Penicillin after hypophysectomy. 
Hypophysectomy was judged to have been complete when, 2 weeks after the 
operation, rats showed <2 g weight gain, a serum T 4 concentration of less than 
1 nmol/1 and a decrease in testicular volume. A corticosterone pellet (C 2505. 
Sigma, St. Louis, USA) weighing 50 mg was implanted s.c., 2 days before 
administration of hormones. 
Hormone administration 
Hormone administration was started 14 days after the initiation of the 
medication (hypothyroid rats) or operation (hypophysectomized rats). 
Hormones were given for 10 consecutive days by s.c. injection twice daily. L-
Thyroxine (Sigma) was dissolved in NaOH (0.1 mol!l) and diluted in 0.9 % 
(w/v) NaCL A dose of 20 !lglkg/day was given in 0.2 mi. Recombinant 
human GH (hGH, Norditropin, Novo-Nordisk. Denmark) in a dose of 2 
IU/kg/day (0.68 mg/kg/day)was administered in 0.1 mVday. After 10 days of 
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substitution, animals were killed by decapitation after 18 h of fasting. Trunk 
blood was collected. 
Analytical methods 
Total serum cholesterol and triglycerides were determined directly. Human 
HDL cholesterol was measured, after precipitation of VLDL and LDL with 
dextran sulfate-magnesium chloride, by enzymatic method (Boehringer testkit 
combination, Boehringer, Mannheim, Germany). Human LDL concentrations 
were calculated according to the formula of Friedewald. The hepatic lipase 
activity in rat liver was determined as described by Jansen et al (1980). The 
activity was expressed as mU/mg liver : 1 mU represents the release of 1 nrnol 
fatty acid from the substrate/min. Concentrations of T4 and T3 were 
determined by radioimmunoassay (Visser et al., 1975). The IGF-I 
concentration in plasma was determined by radioimmunoassay, using a test kit 
(Nichols institute diagnostics, San Juan Capistrano, USA). 
Statistical Methods 
All data are expressed as mean ± S.D. The statistical significance of the 
differences between groups was determined using analysis of variance 
(ANOV A). When significant overall effects were obtained, multiple 
comparisons were made with the Newman-Keuls test. 
RESULTS 
Effects of GH substitution in humans 
After one month of GH substitution cholesterol had decreased by an average 
of 12 % (p<0.05, Figure 8.1), due to a decrease in LDL cholesterol (p<0.05), 
while HDL cholesterol was not affected (Table 8.1). The decrease in LDL 
cholesterol was significant after one month of replacement therapy, but the 
LDL concentration approached basal values after the treatment period of 6 
month. Three month after discontinuation of the treatment LDL cholesterol 
had returned to pretreatment values. LPL activity decreased during GH 
substitution and normalized after withdrawal of treatment, although these 
changes did not reach statistical significance (Table 8.1). HL was not affected 
by GH treatment. GH induced a clear increase in circulating IGF-I and thyroid 
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Figure 8.1: Effects of substitution with GH on individual values of plasma cholesterol. IGF-
I and T 3 concentration. in 8 GH-deficient adults before and after 1 month of 
treatment (each symbcl characterizes one patient). 
Table 8.1: Effects of treatment with GH of 8 GH-deficient adults on lipid 
values, thyroid hormones and IGF-I according to time. Values are 
means ± SD. Significant differences from baseline are indicated 
by an asterisk (p<O.OS by ANOV A). 
GH for GH for GH for GH 3 months 
baseline 1 month 3 months 6 months stopped 
Chol(mM) 5.3 ±0.9 4.6 ± 0.6" 4.9 ± 0.5' 4.8 ± 0.7* 4.9 ± 0.7' 
LDL(mM) 3.25± 1.06 2.69 ± 0.80' 2.91± 0.54 3.05± 0.56 3.20 ± 1.00 
HDL(mM) 0.96± 0.23 0.92 ± 0.17 1.08± 0.29 0.94± 0.21 0.96 ± 0.19 
TG (mM) 2.3 ±0.7 2.3 ± 1.0 1.9 ± 1.0 1.8 ±0.9 1.6 ± 1.2 
LPL(mU/ml) 96 ±33 79 ±22 78 ±22 74 ±20 94 ±35 
HL(mU/ml) 383 ± 91 400 ±83 393 ± 86 372 ± 81 383 ± 108 
T3 (nM) 1.44± 0.36 1.95 ± 0.42' 1.78± 0.36' 1.66 ± 0.48 1.38 ± 0.41 
T• (nM) 92 ± 16 74 ± 15' 72 ±28' 81 ±29 99 ±25 
IGF-I(U!ml) 0.2 ± 0.1 1.6 ± 1.3' 1.6 ± 1.0' 1.2 ± 0.7' 0.2 ± 0.1 
hormone in all but one patient. During the entire GH substitution period 
increased concentrations of T 3 were found (p<0.05), after cessation of 
treatment T 3 decreased to pretreatment levels. Simultaneously with the 
increase in T 3 a fall in T 4 concentration was observed. 
Effects of GH treatment in rats 
Plasma cholesterol concentrations in hypophysectomized and hypothyroid rats, 
were increased as compared to euthyroid controls (p<O.Ol), 4.01 ± 0.37 mM, 
3.71 ± 0.48 mM and 2.17 ± 0.21 mM respectively (Figure 8.2). Treatment 
with GH lowered cholesterol in the GH-deficient hypophysectomized and 
hypothyroid rats, but did not affect the plasma cholesterol concentration of 
euthyroid controls. Normalization of plasma cholesterol concentration was 
obtained by substitution treatment with a combination of GH and T 4- GH 
raised IGF-I concentration in hypophysectomized rats from 0.76 ± 0.14 U/ml 
to 1.62 ± 0.31 U/ml (p<O.Ol). In hypothyroid rats IGF-I concentration 
normalized during treatment with GH as well as with T4 (p<0.03, Figure 8.3). 
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Figure 8.2: Effect of treatment with T 4, GH. or a combination of the two hormones on 
plasma cholesterol concentration in hypophysectomized. hypothyroid or 
euthyroid rats. Values are means± SD for a group of 16 (hypophysectomized 
and hypothyroid rats. black and hatched bars, respectively) or 8 (euthyroid. 
open bars) rats. Data significantly different from control are marked with an 
asterisk (p<0.05). 
The effects of treatment with GH, T 4 or a combination of these two hormones 
on thyroid hormone status are given in Table 8.2. GH treatment of 
hypothyroid or euthyroid rats did not affect the T3 nor T4 concentrations. The 
addition of GH to treatment with T 4 did not change T 3 nor T 4 concentrations 
as compared to treatment with T4 alone in either of the three studied groups. 
DISCUSSION 
Replacement therapy with GH caused a decrease in total serum cholesterol in 
GH-deficient humans as well as in rats. In GH-deficient humans the 
administration of GH lowered the cholesterol concentration only when 
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Table 8.2: Mean (± SD) values of serum thyroid parameters of 8 rats per 
group at the end of 10 days of treatment with Thyroxine (T 4), 
Growth hormone (GH) or a combination of the two hormones. 
T 4 concentration (nM): 
Hypophysectomized 
Control <I 
GH <I 
T• 112±22 
T4 + GH 116 ± 40 
T3 concentration (nM): 
Hypophysectomized 
Control ndO 
GH 0.23 ± 0.03 
T4 3.52 ± 1.03# 
T• + GH 2.60 ± 0.40 
Hypothyroid 
2±4 
<I 
118 ± 29 
120 ± 15 
Hypothyroid 
0.46 ± 0.28 
0.23 ±0.08 
2.63 ± 0.34 
2.80 ± 0.36 
Euthyroid 
56±5 
49±14 
123 ± 14 
133± 13 
Euthyroid 
1.49 ± 0.11 
1.40 ± 0.12 
2.21 ± 0.46 
2.34 ± 0.41 
o od means not detennined. # detennined in EDTA plasma instead of serum. 
baseline cholesterol was above 4.5 mM. This is in accordance with the changes 
in circulating cholesterol levels during GH administration, as observed by 
other investigators (Blacket et a!., 1982; Asayama et a!., 1984; Salomon et a!., 
1989). It supports the hypothesis that GH-activity influences cholesterol 
metabolism in man (Hoogerbrugge-vdLinden et a!., 1989; Chapter 2). The 
mechanism of the cholesterol lowering effect of GH is still unsolved: it 
appears to consist of a decrease in LDL cholesterol, but it is not known 
whether this is the result of a direct effect of the activity of GH (or IGF-I) or 
whether this effect is mediated via an increase in thyroid hormone activity. An 
increase in T3 and a decrease in T 4 levels were observed in patients treated 
with GH, suggesting activation of the peripheral de-iodination of T4. Thyroid 
hormone is generally accepted to stimulate LDL catabolism and might 
contribute to or even totally mediate the observed changes in LDL-cholesterol 
concentrations during GH treatment in man. 
112 Lipoprotein metabolism in hypothyroidism 
5 
4 
'E 
~ 3 
T 2 
"-\2 
Control GH T4 GH+T4 
Figure 8.3: Effect of treatment with T 4. GH. or a combination of the two hormones on 
plasma IGF-1 concentration, in hypophysectomized, hypothyroid or euthyroid 
rats. Values are means ± SD for groups of 8 rats. See also legend to Figure 8.2. 
Data significant different are marked (p<0.05); O=different from 
hypophysectomized controls, *=different from hypothyroid controls). 
During hypothyroidism the synthesis, secretion and activity of GH were shown 
to be deficient (Chernausek and Turner, 1989; Katakami et a!., 1986). 
Thyroid hormone appeared to be necessary for GH gene transcription (Yaffe 
and Samuels, 1984 ). This means that not only hypophysectomized, but also 
hypothyroid rats are GH-deficient (Hoogerbrugge-v.d.Linden et aL, 1990; 
Chapter 3). In these rwo groups of rats replacement therapy with GH led to a 
decrease in total cholesterol, due to a decrease in both LDL and 
HDL-cholesteroL However, in contrast to the human situation, substitution 
with GH in rats did not affect T 3 concentrations. The cholesterol decreasing 
effect of GH appears therefore at least in rats not to be mediated via changes 
in thyroid hormone activity. 
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GENERAL DISCUSSION AND CONCLUSIONS 
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For almost 70 years it is known that deficiency of thyroid hormone induces a 
rise in serum cholesterol (1). The hypercholesterolemia of hypothyroidism 
can be reversed to normal by thyroid hormone replacement (2). In the huge 
amount of (controversial) data with respect to lipid metabolism in 
hypothyroidism. a decreased low-density lipoprotein (LDL) catabolism (3), 
and a decreased hepatic lipase-activity ( 4) are common findings. These effects 
on lipid metabolism are generally interpreted as a direct effect of a deficiency 
in thyroid hormone. In 1970 it was described that hypercholesterolemia in 
thyroidectomized rats can be prevented, not only by substitution with thyroid 
hormone, but also by growth hormone (GH) (5). Later it was shown that GH 
can lower the concentration of plasma cholesterol in humans, for example in 
GH-deficient adults (6), and in patients with primary hypercholesterolemia 
(7). Recently, it was revealed that thyroid hormone regulates GH gene tran-
scription (8) and it was shown that in hypothyroid patients as well as in 
hypothyroid rats, GH secretion and plasma IGF-I concentration are reduced 
(9). 
In this thesis, the effects of GH on lipid metabolism, especially during 
hypothyroidism were investigated. We studied whether the hypercholesterol-
emia present in hypothyroidism has to be attributed to a deficiency in thyroid 
hormone, a deficiency in GH or to both of them. Schematically this question is 
depicted in Figure 9 .1. 
TH Cholesterol l 
/ 
GH t 
Fi,gure 9.1: Schematic representation of the interaction that might occur between thyroid 
hormone (TH) and growth hormone (GH) as well as their effects on the 
concentration of plasma cholesterol. 
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The evaluation of the separate effects of either GH or thyroid hormone on 
lipoprotein metabolism, is complicated; substitution treatment of hypothyroid 
subjects with thyroid hormone will restore the pituitary secretion of GH and 
normalize the activity of both hormones. Next to this, replacement therapy of 
human adults with GH has been reported to stimulate thyroid hormone activity 
by increasing the peripheral de-iodination of T4 (10). In humans as well as in 
rats, the effects of replacement therapy with thyroid hormone and GH on 
plasma lipoprotein concentrations and hepatic lipase activity were studied. We 
used hypophysectomized and methimazole- induced-hypothyroid rats, to 
investigate the individual effects of GH and thyroid hormone on lipoprotein 
metabolism in the hypothyroid state. Special attention was paid to the 
determinants (LDL-receptor) of plasma LDL-cholesterol and the activity of 
hepatic lipase, as these two parameters are generally reported to be affected in 
hypothyroidism. 
EFFECTS OF GH AND THYROID HORMONE ON THE 
CONCENTRATION OF CIRCULATING LDL CHOLESTEROL. 
An indication that the concentration of plasma LDL cholesterol and the 
activity of GH are related was obtained in hypothyroid women (Chapter 2). 
In these women GH-activity was measured by determination of insulin-like 
growth factor-I (IGF-I), as most actions of GH are assumed to be mediated by 
IGF-I. Multivariate regression analysis of the dependent variable LDL 
cholesterol, against the concentration of plasma IGF-I and free T 4, showed 
that the concentration of LDL cholesterol is related to IGF-I and that this 
relation is independent from the concentration of free T 4· This suggests that 
IGF-I rather than thyroid hormone determines the concentration of plasma 
cholesterol in patients with hypothyroidism. 
GH replacement therapy of hypophysectomized and hypothyroid rats 
reduces the plasma concentration of LDL cholesterol (Chapter 3). The LDL 
cholesterol decreasing effect of replacement therapy with GH was less 
pronounced than that with T4 (Chapter 3 and 4). In hypothyroid rtas 
combined therapy with the two hormones appeared to have an additive effect 
on the decrease in circulating LDL cholesterol (Chapter 4). The decrease of 
the concentration of plasma LDL cholesterol, following GH replacement, was 
accompanied by an increase in the concentration of LDL receptor mRNA in 
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the liver. In addition the expression of the LDL receptor in liver was 
enhanced (Chapter 5). This suggests that GH stimulates LDL catabolism by an 
increase in the number of active LDL receptors in the liver. GH may exert its 
effect either directly or indirectly via a lowering in the intracellular 
concentration of cholesterol. An indirect effect resulting from consumption of 
cholesterol e.g. for cell membrane synthesis, is likely to occur; the pubertal 
hypothyroid rats treated with GH showed a significant weight increase, while 
untreated hypothyroid rats did not. 
Although GH replacement increased the levels of mRNA for the LDL receptor 
and the expression of the LDL receptor to control values, it did not normalize 
the concentration of plasma LDL cholesterol. The addition of thyroxin to GH 
therapy was necessary to normalize the concentration of circulating LDL 
cholesterol in hypophysectomized rats. For some other hepatic mRNA's it has 
been shown that thyroid hormone enhances the expression of GH-stimulated 
mRNA's at a pretranslation level (e.g. 5 alpha-reductase and 16 
alpha-hydroxylase, 11). Our data suggest a similar mechanism to occur for 
hepatic mRNA of the LDL receptor, in which GH stimulates the transcription 
and thyroid hormone might enhance posttranscription. Another explanation 
for these results might be, that once mRNA for LDL receptor is formed, it 
will be translated but the translation product remains in the endoplasmatic 
reticulum instead of reaching the plasma membrane. The cellular membrane 
preparations we used to study the LDL receptor expression consisted of a 
mixture of membranes from intracellular compartments and plasma 
membranes. This method is unable to distinguish an erroneously located 
nonfunctional LDL receptor protein from one at the physiological site of 
action. Pulse chase studies are needed to disentangle this mechanism. 
GH replacement in rats led to an increase in the concentration of plasma IGF-
I. The results obtained in hypothyroid women suggested that IGF-I mediates 
the effects of GH on the concentration of plasma LDL cholesterol. This was 
consistent with the effects found in in vitro experiments; in a human 
hepatocyte cell-line it was shown that LDL binding and internalization was 
stimulated following incubation with IGF-I, but not with GH. These results 
support the hypothesis that the effects of GH on the LDL receptor are 
mediated by IGF-I (Chapter 6). A replacement experiment with IGF-I in 
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hypothyroids in vivo has yet to be done, in order to prove the hypothesis that 
the deficiency of IGF-I that occurs in hypothyroidism is important for the 
hypercholesterolemia during this condition. Recently it was reported that the 
administration of IGF-I to patients with Laron type dwarfism caused a 
decrease in plasma cholesterol concentration (12). As these patients are 
characterized by high plasma levels of GH, but an inability to generate 
endogenous IGF-I, due to a GH receptor defect, these results support the 
previous hypothesis. 
Once the diagnosis hypothyroidism is made, treatment of this patient with 
thyroid hormone can not be postponed to study the effects of GH in this 
condition. In order to investigate the effects of GH (or IGF-I) on the con-
centration of plasma cholesterol, we studied GH-deficient adults before, 
during and after long-term GH replacement therapy. GH replacement in these 
patients led to a decrease in plasma (LDL) cholesterol and a rise of the level of 
circulating IGF-1, but also in the concentration of serum T3 (Chapter 8). This 
means that in humans next to a "direct" effect of GH I IGF-I on the 
concentration of plasma. cholesterol, GH might also affect cholesterol 
T4 T3 LDL 
• 
~ cholesterol ~ 
I / I I 
I 
I IGF-1 t 
I 
t/ I I I GH 
Figure 9.2: Diagram of the effects ofT 3 on the activity of growth hormone (GH) and 
plasma LDL cholesterol concentration GH enhances the de-iodination ofT 4 and 
decreases the concentration of circulating LDL cholesterol. the latter effect is 
mediated by IGF-1. The decrease in plasma LDL concentration induced by 
replacement therapy with T4 is more potent than the decrease obtained by GH 
replacement therapy. 
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metabolism via T 3· In rats we did not observe an increase in T 3 concentration 
during replacement therapy with GH. In the human situation GH and thyroid 
hormone stimulate each others activity; an outline of the situation assumed to 
exist in humans is shown in figure 9 .2. 
EFFECTS OF GH AND THYROID HORMONE ON HEPATIC 
LIPASE 
In rats the effect of replacement treatment with GH on the activity of hepatic 
lipase in the liver, appears to differ from the effect of replacement with 
thyroid hormone: GH replacement treatment of hypophysectomized rats, 
enhanced the activity of hepatic lipase, while substitution with thyroid 
hormone did not affect the activity of this enzyme. However, replacement with 
a combination of thyroid hormone and GH, stimulated the activity of hepatic 
lipase more than GH alone. Thus only in the presence of GH, thyroid hormone 
seems to stimulate hepatic lipase activity. In other words, GH appears to be a 
permissive factor for the stimulatory effect of thyroid hormone on hepatic 
lipase activity in hypothyroidism (Chapter 3 and 4 ). A diagram of this 
situation is given in figure 9.3. 
TH 
------------- GH t 
-
t HL 
Figure 9.3: Diagram of the effects of GH and thyroid hormone (TH) on the activity of 
hepatic lipase (HL) in rats. GH is a more potent stimulator of HL-activity than 
TH. and serves as a permissive factor for the effects of TH on HL. 
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In hypothyroid rats the concentration of mRNA for hepatic lipase in liver cells 
was found to be decreased. It returned to control values after treatment with 
GH, suggesting a stimulatory effect of GH on the synthesis of this enzyme 
(Chapter 7). Hepatic lipase exerts its function bound to the sinusoidal cells, 
from which it can be released by the administration of heparin. Treatment of 
hypothyroid rats with GH normalized the activity of hepatic lipase in post 
heparin plasma, indicating that GH stimulates HL-activity at its site of action. 
Our results in rats suggest that GH stimulates HL synthesis. However, freshly 
isolated liver parenchymal cells from hypothyroid rats, substituted for 10 days 
with GH, secreted the same amount and activity of HL as cells from 
hypothyroid rats, i.e. approximately 60 % of the amount produced by cells 
from control rats (unpublished data). A GH induced increase in HL synthesis 
has yet to be shown, e.g. by incubation with GH of liver parenchymal cells in 
maintenance culture. So far, the increased activity of HL bound to the vascular 
endothelium might as well be caused by a GH induced increase in HL binding 
places. However, modulation of the mass of specific mRNA species is a major 
mechanism of growth hormone action (13). It is unlikely that a significant 
change in the concentration of hepatic lipase mRNA occurs without an 
increase in the protein encoded by that mRNA. In parallel to the effects of GH 
on LDL receptor mRNA and function, we suggest that HL protein synthesis is 
enhanced but that the protein might accumulate during the complicated process 
that is necessary to form an active enzyme. Pulse chase experiments are 
needed the investigate this process. Thyroid hormone is known to regulate 
hepatic enzymes by multiple mechanisms, involving both transcriptional and 
posttranscriptional steps (14). The additive stimulatory effects of thyroid 
hormone in the presence of GH, suggests that GH stimulates the transcription 
while thyroid hormone is necessary for posttranscriptional processes (such a 
regulatory mechanism was shown to occur for apolipoprotein B mRNA) (15). 
In humans the effects of GH and thyroid hormone on the activity of HL are 
not clear. Comparable to the situation in rats the activity of HL was decreased 
in hypothyroid patients and normalized after substitution with thyroid 
hormone (Chapter 2). However, the activity of HL in GH deficient euthyroid 
individuals was normal and replacement with GH did not affect its activity 
(Chapter 8). Perhaps euthyroid GH deficient patients are not deprived of all 
growth hormone activity, as thyroid hormone can induce some IGF-I 
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production. In contrast, in patients with acromegaly, having a high 
concentration of circulating GH, HL is increased. We speculate that growth 
hormone does have a stimulating effect on the activity of hepatic lipase in 
humans too, but that this can only be shown either during absolute deprivation 
of growth hormone as exists in profound hypothyroidism, or in the presence 
of excessive amounts (e.g. acromegaly). 
GENERAL CONCLUSIONS 
From the studies reported in this thesis we conclude that the dyslipidemia of 
hypothyroidism has to be attributed both to thyroid hormone and GH. 
Schematically this is depicted in figure 9.4. 
TH 
t HL 
/ 
GH t 
LDL-
cholesterol 
Figure 9.4: Schematic representation of the supposed interaction between thyroid hormone 
(fH) and growth hormone (GH), as well as their effects on the concentration of 
circulating LDL·cholesterol and the activity of hepatic lipase (HL) in the rat. 
Thyroid hormone and GH stimulate each others activity; GH enhances the de-
iodination of T4 in humans, while T4 stimulates GH synthesis and secretion in 
the pituitary and the number of GH receptors in rat liver (16). Although our 
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experiments in rats clearly demonstrate that thyroid hormone and GH can act 
independently, it is likely that in the intact animal these hormones will also 
interact to regulate LDL receptor and hepatic lipase activity. The precise 
mechanism by which these hormones stimulate cholesterol metabolism is (still) 
not known. Thyroid hormone might act as a positive regulator of 
OR-stimulated hepatic mRNA levels, active in cholesterol metabolism. 
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An increased concentration of circulating low-density lipoprotein (LDL) 
cholesterol, is causally related to an increased risk of coronary heart disease. 
There is substantial evidence that lowering LDL-cholesterollevels as well as 
increasing high-density lipoprotein (HDL)-cholesterol concentration, will 
reduce the incidence of coronary heart disease. Hormones are important 
regulators of the concentration of these lipoproteins. However, the effects of 
most hormones on lipid metabolism are complex and poorly understood. 
Abnormalities in hormone secretion may participate in the pathophysiology of 
lipoprotein aberrations and contribute to the atherogenic risk accompanying 
common diseases such as hypothyroidism. Understanding of the factors that 
control cholesterol metabolism may provide new openings in the treatment of 
dyslipidemia. In this thesis the disturbance of lipid metabolism during hypo-
thyroidism were studied. 
Since early in this century it is known that hypothyroidism causes 
hypercholesterolemia. Nowadays we know that this hypercholesterolemia 
results from an increase in LDL-cholesterol. In man the influence of hypothyr-
oidism on the concentration of total plasma HDL-cholesterol is rather 
equivocal, but the activity of hepatic lipase, a key enzyme in HDL metabolism, 
is uniformly reported to be decreased. These changes in lipoprotein meta-
bolism during hypothyroidism have been ascribed to direct effects of the 
decreased circulating thyroid hormone (TH). However, as TH is necessary for 
the production and secretion of growth hormone (GH); hypothyroid 
individuals have a deficiency of GH-activity too. In other conditions GH itself 
is thought to affect lipoprotein metabolism. We studied the effects and 
involvement of TH, GH and IGF-I on lipid metabolism, especially in hypo-
thyroidism. 
In patients with hypothyroidism plasma lipids and the level of circulating IGF-
I, a mediator for GH action, were measured. As compared to healthy controls, 
an increased concentration of plasma LDL-cholesterol and a decreased IGF-I 
concentration were found. The concentration of plasma LDL-cholesterol 
appeared to be highest in those patients with the lowest concentration of 
plasma IGF-I. In a multivariate regression analysis of LDL-cholesterol, as the 
dependent variable, against IGF-I and free T 4 a significant negative correla-
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tion between IGF-I and LDL-cholesterol concentrations but not between free 
T4 and LDL-cholesterol was shown. This suggests that the effect of IGF-I on 
cholesterol metabolism is directly on the LDL-cholesterol metabolism. 
Furthermore, a cholesterol decreasing effect of GH was seen in euthyroid, but 
GH-deficient adults. Substitution of these patients with GH resulted in a 
reduction of the concentration of plasma LDL-cholesterol. However in this 
group of patients GH increased the concentration of circulating T 3, while 
serum T 4 concentration falL In these euthyroid patients it could not be 
concluded whether the decrease in plasma cholesterol concentration was the 
result of GH (or IGF-I) activity itself, or an indirect effect via enhancement of 
the conversion of T 4 into T 3· 
Hypothyroidism is a serious disease; once it is diagnosed, substitution with TH 
has to be started. Postponement of this substitution, in order to study the 
effects of GH on lipid metabolism in hypothyroid patients is not permissible. 
For this reason we used hypophysectomized and hypothyroid rats as a model 
to study the effects of GH and TH on lipoprotein metabolism in vivo. Single 
GH treatment or GH treatment in addition to T4 therapy did not affect the 
concentration of either T 4 or T 3 in hypophysectomized, hypothyroid and 
euthyroid rats. However treatment of hypophysectomized rats with GH, 
decreased the plasma LDL-cholesterol concentration. We concluded that at 
least in rats the cholesterol lowering effect of GH is not mediated by TH. 
Replacement with TH was more potent than replacement with GH in the 
regulation of LDL-cholesterol concentration. 
In hypothyroid rats the LDL-cholesterol decreasing effect of GH was shown to 
be accompanied by a rise in the level of mRNA for the LDL-receptor in the 
liver. The LDL-receptor expression in the liver was stimulated too by GH. 
This indicates that GH stimulates the number of active LDL-receptors by an 
increase in LDL-receptor synthesis. A human liver tumor cell line (HepG2), 
was used to show that LDL-receptor activity, both LDL binding and inter-
nalization, can be stimulated by incubation with IGF-L In contrast incubation 
with GH did not affect LDL-receptor function. This suggests that the effects of 
GH on the concentration of LDL-cholesterol in hypothyroids are mediated by 
IGF-L 
The activity of hepatic lipase is decreased both in hypothyroid humans as well 
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as in rats and increases during substitution with TH. In hypophysectomized 
and hypothyroid rats treatment with GH stimulated the activity of hepatic 
lipase in the liver. TH also stimulated hepatic lipase-activity, but only in the 
presence of GH. The administration of GH to hypothyroid rats increased both 
the concentration of mRNA for hepatic lipase and the activity of hepatic lipase 
in liver homogenates. Hepatic lipase exerts its function bound to the sinusoidal 
cells, from which it can be released by the administration of heparin. 
Treatment of hypothyroid rats with GH normalized the activity of hepatic 
lipase in post heparin plasma. This indicates that GH stimulates hepatic lipase 
synthesis (determined by mRNA), resulting in an increased activity at its site 
of action, the vascular endothelium of the liver. 
In view of the experiments presented in this thesis, it is concluded that the 
dyslipidemia that occurs in hypothyroidism results from a deficiency in both 
TH and GH. In hypothyroid rats it was shown that the concentration of 
circulating LDL-cholesterol is mainly determined by TH, while GH has a 
minor LDL-cholesterol decreasing effect. On the other hand GH has a 
prominent role in the regulation of hepatic lipase-activity. GH exerts its effect 
on LDL-cholesterol and hepatic lipase-activity via an induction of hepatic 
mRNA encoding for the LDL-receptor and for hepatic lipase. 
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Een verhoogde concentratie van cholesterol circulerend in low-density lipo-
proteiilen (LDL), is mede verantwoordelijk voor een toegenomen risico op de 
voortijdige ontwikkeling van hart- en vaatziekten. Er zijn gegronde aan-
wijzingen dat verlaging van de plasma concentratie van LDL-cholesterol of 
verhoging van de plasma concentratie van cholesterol in high-density lipo-
prote"inen (HDL), het optreden van hart- en vaatziekten vermindert. 
Hormonen hebben een regulerende invloed op de concentratie van deze lipo-
protelnen. De wijze waarop hormonen het vetrnetabolisme belnvloeden is 
complex en slechts gedeeltelijk bekend. Een afwijking in de normale hormoon-
produktie kan leiden tot ziekelijke veranderingen in het metabolisme van lipo-
protelnen en aanleiding geven tot een versnelde ontwikkeling van athero-
sclerose, zoals optreedt bij patienten met hypothyreoldie. Kennis van de 
factoren die in het cholesterolmetabolisme van belang zijn, kan leiden tot een 
meer specifieke behandeling van dyslipidemie. In het onderzoek beschreven in 
dit proefschrift is de regulatie van het lipidenmetabolisme tijdens hypo-
thyreoldie bestudeerd. 
Sinds het begin van deze eeuw is bekend dat hypothyreoldie een hyper-
cholesterolemie veroorzaakt. De laatste jaren is bekend geworden dat deze 
hypercholesterolemie het gevolg is van een toegenomen plasma LDL-chol-
esterol concentratie. Bij de mens heeft hypothyreoldie geen duidelijk effect op 
de totale plasma concentratie van HDL-cholesterol; wei is een verlaging van de 
activiteit van hepatisch lipase beschreven. Hepatisch lipase wordt verondersteld 
een rol te spelen in het HDL-metabolisme. De veranderingen in het lipiden-
metabolisme tijdens hypothyreoldie zijn toegeschreven aan een verminderde 
aanwezigheid van schildklierhormoon. Aangezien schildklierhormoon nood-
zakelijk is voor de produktie en secretie van groeihormoon (GH), is er tijdens 
hypothyreoldie niet aileen een verlaagde schildklierhormoon-activiteit, maar 
ook een verminderde activiteit van GH aanwezig. Ook van GH is bekend dat 
dit het lipoprotelnemetabolisme beinvloedt. Wij bestudeerden daarom het 
afzonderlijk effect van GH en schildklierhormoon op het lipidenmetabolisme, 
met name gedurende hypothyreo·idie. 
Iti patienten met hypothyreoldie werden de plasma lipiden concentraties en de 
concentratie van circulerend IGF-I, een maat voor de activiteit van groei-
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hormoon, gemeten. Vergeleken met gezonde controle personen werd in deze 
patienten, zowel een verhoogde concentratie van LDL-cholesterol, als een ver-
laagde IGF-l concentratie, gevonden. De hoogste plasma LDL-cholesterol 
concentraties bleken aanwezig te zijn bij patienten met de laagste plasma IGF-l 
concentraties. In een multivariate regressie-analyse van de concentraties van 
LDL-cholesterol, tegen IGF-I en vrij T 4, werd een negatieve correlatie tussen 
LDL-cholesterol en IGF-I gevonden, maar niet tussen LDL-cholesterol en de 
vrije T4 concentratie. Dit suggereert dat de activiteit van GH, onafhankelijk 
van schildklierhorrnoon, de LDL-cholesterol concentratie be'invloedt. Ook bij 
patienten met een normale schildklierfunctie, maar een deficientie voor GH, 
werd aangetoond dat toediening van GH de plasma LDL-cholesterol 
concentratie verlaagt. Bij deze euthyreote patienten bleek echter, dat tijdens 
behandeling met GH, de serum concentratie van T3 werd verhoogd en de 
serum T 4 concentratie werd verlaagd. Uit deze gegevens bij patienten met een 
norrnale schildklierfunctie kon daarom niet worden geconcludeerd of de 
verlaging van de plasma LDL-cholesterol concentratie tijdens behandeling met 
GH, een gevolg was van de GH activiteit zelf, of werd veroorzaakt door een 
toegenomen omzetting van T 4 in het biologisch actieve T 3• 
Hypothyreoldie is een emstige ziekte waarbij zodra de diagnose is gesteld 
dient te worden begonnen met behandeling, die bestaat uit het toedienen van 
schildklierhormoon. Uitstel van behandeling, om het effect van GH te 
bestuderen, is derhalve niet gewenst. Om het afzonderlijke effect van 
schildklierhorrnoon en GH op het lipidenmetabolisme in vivo te kunnen 
bestuderen, hebben wij als model gehypofysectomeerde en hypothyreote ratten 
gebruikt. Toediening van GH aan gehypofysectomeerde, medicamenteus 
hypothyreoot gemaakte of euthyreote ratten, veroorzaakte geen verandering in 
de concentratie van circulerend T 3 en T 4 . Behandeling van gehypofysecto-
meerde ratten met GH leidde wei tot een verlaging van de plasma LDL-
cholesterol concentratie. Geconcludeerd werd dat, tenminste in de rat. het 
cholesterol verlagend effect van GH niet wordt gemedieerd door schildklier-
hormoon. Substitutie van schildklierhormoon bleek de LDL-cholesterol con-
centratie meer te verlagen dan substitutie van GH. 
In met GH behandelde hypothyreote ratten werd naast een LDL-cholesterol 
verlagend effect, een toename in de concentratie van mRNA coderend voor de 
LDL-receptor in de lever waargenomen. De expressie van de LDL-receptor 
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bleek eveneens te worden gestimuleerd door behandeling met GH. Dit 
suggereert dat GH het aantal actieve LDL-receptoren doet toenemen via een 
verhoogde synthese van deze receptoren. In een humane tumorcellijn 
(HepG2). werd aangetoond dat zowel de binding als de internalizatie van LDL 
door de receptor. kon worden gestirnuleerd door incubatie met IGF-I, terwijl 
incubatie met GH de LDL-receptoractiviteit niet veranderde. Dit rnaakt waar-
schijnlijk dat het effect van GH op de concentratie van LDL-cholesterol wordt 
gemedieerd door IGF-L 
De activiteit van hepatisch lipase was verlaagd, zowel in hypothyreote patient-
en als in ratten, en nam toe tijdens substitutie met schildklierhormoon. 
Behandeling van gehypofysectomeerde en hypothyreote ratten met GH 
stimuleerde de activiteit van hepatisch lipase in gehomogeniseerd leverweefsel, 
terwijl behandeling met schildklierhormoon de activiteit van hepatisch lipase 
aileen kon verhogen in aanwezigheid van GH. Toediening van GH aan 
hypothyreote ratten leidde niet aileen tot een toename in activiteit van 
hepatisch lipase, maar ook tot toename van de mRNA concentratie voor 
hepatisch lipase in leverweefsel. Hepatisch lipase oefent haar functie uit 
gebonden aan de sinusoidalecellen van de lever, en kan van deze plaats worden 
losgemaakt door toediening van heparine. Behandeling van hypothyreote rat-
ten met GH normaliseerde de activiteit van hepatisch lipase in het postheparine 
plasma. Hieruit werd geconcludeerd dat GH de synthese van hepatisch lipase 
stimuleert, met als gevolg een toename van de hoeveelheid aan endotheelcellen 
gebonden enzym. 
Uit de in dit proefschrift beschreven experimenten wordt geconcludeerd dat 
de afwijkingen in het lipidenmetabolisme tijdens hypothyreoidie, worden ver-
oorzaakt door een deficientie van zowel schildklierhormoon als GH. De con-
centratie van circulerend LDL-cholesterol bleek. althans in de rat. voorname-
lijk te worden bepaald door schildklierhormoon, terwijl GH hierin een onder-
geschikte rol vervult. In de regulatie van de activiteit van hepatisch lipase 
bleek de rol van GH belangrijker. Het effect van GH op de concentratie van 
LDL-cholesterol en de activiteit van hepatisch lipase verloopt via inductie van 
mRNA coderend voor respectievelijk de LDL-receptor en hepatisch lipase. 
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tot internist dank; aan hem en aan Paula Schuyf dank ik tevens mijn plezier in 
de endocrinologie. 
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Rini Baggen, die mijn interesse voor de behandeling van hypercholesterolemie 
aanwakkerde en mij het cholesterol-vakgebied inleidde. 
Loek de Heide en Carola Eggermon t -Zillikens, voor de verhelderende 
discussies. 
Coby Voorvelt dank ik omdat zij een dee! van de zorg voor Pieter op zich 
nam. 
Het meest bedank ik jou, Peter, voor je altijd aanspreekbare interesse in mijn 
werk. Je kritische kanttekeningen (hoewel soms frustrerend) waren 
onmisbaar; aan jou en aan onze zoon wil ik dit proefschrift opdragen. 
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CURRICULUM VITAE 
De schrijfster van dit proefschrift is geboren op 26 juli 1958 te Delft. Na het 
behalen van het diploma Atheneum-B aan het Christelijk Lyceum te Delft, 
werd in 197 6 aangevangen met de studie Geneeskunde aan de Erasmus 
Universiteit te Rotterdam. Het doctoraal examen werd in 1981 (Cum Laude) 
afgelegd en in 1983 het arts examen (Cum Laude). 
In april 1983 began zij de opleiding tot internist in het Diakonessenhuis Refaja 
te Dordrecht (opleider destijds: C.Verdoom). In mei 1985 werd de opleiding 
tot internist voortgezet in het Academisch Ziekenhuis Dijkzigt op de afdeling 
Inwendige Geneesk.'Unde ill (opleider: Prof. Dr. J.C. Birkenhager). Tijdens de 
opleiding werd aangevangen met het in dit proefschrift beschreven onderzoek. 
Op 1 mei 1988 volgde inschrijving in het specialisten register. Vanaf 1 
September 1988 is zij als internist verbonden aan de afdeling Inwendige 
Geneeskunde ill (afdelingshoofd: Prof. Dr. J.C. Birkenhiiger), waar het in dit 
proefschrift beschreven onderzoek werd verricht. 
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